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Summary 
Background 
Danshen (Salvia miltiorrhiza), a traditional Chinese medicinal herb has been well 
documented in the treatment and prevention of vascular disease, however the exact 
mechanisms of actions of Danshen are still not fully understood.  Given the importance 
of reactive oxygen species (ROS) in the pathogenesis of oxidative-stress related 
cardiovascular diseases, the main objective of this study is to investigate the effects of 
Australian grown Danshen extracts and its’ active compounds on ROS productions in cell 
free and vascular tissue systems.  Another objective of the study is to review the clinical 
adverse reactions and drug reactions of Danshen. 
 
Methodology 
To determine the effects of Danshen extracts and compounds on ROS generation in a cell 
free system.  Xanthine oxidase (XO)/ hypoxanthine (HX) reaction was used and the 
ROS level was determined by lucigenin enhanced chemiluminescence assay using 
96-well plates.  Triplicates were treated with either superoxide dismutase (SOD) or 
different concentrations of Australian grown Danshen extracts or Danshen compounds.  
Lucigenin was added in triplicates to serve as background reading.  The optiplate was 
read in the FLUOstar OPTIMA Microplate reader for 12 cycles at 5 seconds per well. 
 
To determine the effects of Danshen extracts and Danshen compounds on vascular 
superoxide (O2
-) production, rat aortic rings were prepared and placed in 24-well plates 
and incubated at 37℃ for 45 minutes in the absence or presence of Nicotinamide adenine 
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dinucleotide phosphate (NADPH), Danshen extracts/ compounds, Diethyldithiocarbamate 
(DETCA) or diphyleneiodonium chloride (DPI).  During incubation period, the optiplate 
was prepared with lucigenin with or without NADPH, DPI and Danshen extracts or 
Danshen compounds.  Background reading was conducted using the FLUOstar 
OPTIMA Microplate reader for 12 cycles at 5 seconds per well.   
 
To conduct a literature review on clinical adverse reactions and drug interactions of 
Danshen, different search terms including “clinical”, “adverse”, “reactions”, “events”, 
“drug”, “Danshen”, and “Salvia miltiorrhiza” and their combinations were used for 
searching major databases including PubMed, Proquest and CINHAL. 
 
Results 
In the cell free system, the ROS generation by XO/ HX was abolished by SOD (250 U/ml), 
and significantly inhibited by Danshen aqueous (0.05-0.5mg/ml) and ethanol (0.01 and 
0.1mg/ml) extracts, as well as by Danshen active compounds, Tanshinone IIA (TanIIA) 
(0.5µM), Salvianolic acid B (SalB) (0.1-1 µM) and Danshensu (DSS) (1-50 µM).  The 
inhibition of ROS generation by both Danshen extracts and active compounds were 
concentration dependent. 
 
In the rat aorta, DPI significantly inhibited the nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH oxidase) derived O2
- generation.  The Australian grown 
Danshen aqueous extract and ethanol extract inhibited NADPH oxidase activity but only at 
high concentrations (0.5 mg/ml and 0.1 mg/ml, respectively).  SalB (1 and 10 µM) and 
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DSS (1-50 µM) significantly inhibited NADPH oxidase, whilst TanIIA at concentrations 
of 1nM – 0.5µM did not significantly inhibit NADPH oxidase.   
 
Overall, Danshen extracts, both aqueous and ethanol, and active compounds (TanIIA, SalB 
and DSS) inhibited ROS generations at a lower concentration in cell free system than their 
inhibitions of NADPH oxidase derived O2
- in the aortic vascular tissue.   
 
The review of clinical trials and case reports have revealed that the clinical adverse 
reactions of Danshen include gastrointestinal reactions, thirst, headache, elevation of 
glucose, dry cough, dyspnoea and fatigue.  Studies in vitro and in vivo indicate that 
Danshen preparations and compounds may interact with warfarin and human 
cytochrome-p450, an enzyme involved in drug metabolism, in particular CYP1A2, 
CYP2C9, CYP2D6 and CYP3A4.  However, a small clinical trial of healthy subjects also 
suggested that Danshen did not influence the metabolism of the isozyme CYP1A2. 
 
Conclusion 
Australian grown Danshen extracts and related bioactive compounds have been 
demonstrated to be effective in scavenging ROS generation in a cell free system and 
NADPH oxidase derived O2
- generation in vascular tissue.  Overall, Danshen extracts, 
both aqueous and ethanol, and their active compounds (TanIIA, SalB and DSS) exhibited 
stronger activity in a cell free system than in the aortic vascular tissue.  Such actions of 
Danshen may contribute to its’ pharmacological actions.  On the other hand, certain 
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adverse reactions and potential herb-drug interactions have been reported with Danshen, 
which may have clinical implications. 
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Chapter One 
 
General Introduction 
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1.1 Introduction of Danshen  
 
1.1.1 Chinese Herbal Medicine 
Chinese herbal medicine (CHM) is a major form of traditional Chinese medicine (TCM) 
practice.  It involves a prescription of a mixture of medicinal herbs, with the occasional 
use of inorganic materials and animal parts.  Traditionally, CHM’s are prepared as 
decoctions from fresh or dried crude herbs with minimal industrial processing.  
Nowadays, CHM’s are also made available in manufactured tablets, capsules and pills.  In 
a broad sense, CHM is a type of complementary and alternative medicine (CAM), which 
includes a wide diverse range of therapies such as natural products, mind and body 
medicine, and manipulative-based practices (NCCAM 2011). 
 
It has been estimated by the World Health Organization (WHO) that 60-80% of the 
world’s population relies on non-conventional medicine or CAM, mainly of botanical 
origins, as their primary form of health care (Akerele 1993), especially in many Asian 
and African countries.  In the last several decades, CHM has also been gained increasing 
popularity in many Western countries, including Australia (Eisenberg, Davis et al. 1998).  
Traditional herbal medicines have been estimated to have a worldwide annual market of 
US $60 billion and with an approximate estimate of AUD $2 billion annual market in 
Australia (WHO 2003).  A recent population-based survey conducted in Australia found 
that 68.9% of the Australian population are CAM users, with 7% of survey participants 
indicating their use of CHM (Xue, Zhang et al. 2007).  This is consistent with the steady 
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increase of CAM use by the general population, highlighting the trend of consumer 
attitudes toward CAM (Xue, Zhang et al. 2007).   
 
1.1.2 The efficacy of CHM 
The efficacy of CHM is becoming well recognised against various pathological and disease 
states including functional constipation (Cheng, Bian et al. 2011), colorerectal cancer 
(Zhong, Chen et al. 2012), management of obesity (Lenon, Li et al. 2012) and female 
infertility (Ried and Stuart 2011).  In general, CHM has wide clinical application in areas 
such as internal medicine, gynaecology, paediatrics, traumatology, external medicine, 
dermatology, emergency medicine and eye, ear, nose and throat. (Miyata 2007; Kang 
2008; Kiefer, Pitluk et al. 2009).   
 
One example of CHM is Salvia miltiorrhiza (Danshen), which has long been used for the 
treatment of cardiovascular disease including anti-oxidant and anti-inflammatory activity, 
and shown to possess anti-microbial, anti-viral and anti-cancer properties (Wang 2010).  
(See Section 1.4 for more detail). 
 
1.1.3 The safety of CHM 
Generally speaking, CHM is safe when used properly under the guide of the TCM theory.  
However, it is not risk free.  Adverse drug reactions (ADR) of CHM have been 
previously reported (Bensoussan and Myers 1996) especially with a small number of toxic 
herbs including Lobelia chinensis Loureiro (Ban Bian Lian), Aconitum carmichaeli Debx 
(Zhi Fu Zi) and Ephredra sinica Stapf (Ma Huang) (CMRBV Sep 2009), and the 
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possibility of several Chinese herbal products that may contain toxic aristolochic acid 
including Caulis Clematidis Akebiae (Mu Tong) and Radix Stephaniae Tetrandrae (Fang 
Ji) (Wooltorton 2004). 
 
In Australia, reporting of adverse effects of any medication, whether alternative or 
conventional is acknowledged to the Adverse Drug Reactions Advisory Committee 
(ADRAC).  To date, ADRAC has received 154 reports relating to CAM use in 25 years 
(Boyd, I. 1997).  Given the widespread use of CAM, this low number of reports suggests 
that CAM has either a low risk of adverse effects or that effects are significantly under 
reported.  It is suggested that CAM risks may be under reported due to ADRAC not 
actively encouraging the reporting of adverse effects by practitioners and consumers of 
alternative medicine.  CAM use is not routinely included in patients’ drug histories or in 
reports of adverse effects, and the public perception that `natural’ products are safe may 
bias against an association being made between CAM products and adverse effects (Boyd, 
I. 1997).  Thus, it is important to monitor more closely the potential of ADR’s and 
herb-drug interactions in order to ensure the safe practice of CHM. 
 
1.1.4 Danshen  
The Chinese herb Danshen is the dried root and rhizome of Salvia miltiorrhiza Bunge with 
Chinese names including Chi Shen and Zi Dan Shen, English names of Chinese sage, red 
sage, red sage root or salvia root and a pharmaceutical name of Radix Salviae miltiorrhizae 
(Chen 2004; Wang 2010).  It is a perennial flowering plant, highly valued for its’ roots in 
Traditional Chinese Medicine (TCM) (Wang 2010).  The plant is a deciduous perennial 
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native to China and Japan and grows between 30-60 cm high between 90-1200m elevation, 
with preference for grassy places in forests, hillsides and along stream banks in the west 
and southwest provinces of China (Wang 2010).  
 
 
 
 
Fig. 1.1 Dried Radix Salviae miltiorrhiza Bunge 
 
 
 
Fig. 1.2  Radix Salviae miltiorrhiza Bunge roots 
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Fig. 1.3  Radix Salviae miltiorrhiza Bunge plants 
 
 
 
1.1.4.1 Origin of Danshen 
The original source of Danshen was noted in Shen Nong Ben Cao Jing (Divine 
Husbandman’s Classic of the Materia Medica) in the second century around 100 A.D. 
(Chen 2004).  The TCM description of the properties of Danshen (Salvia miltiorrhiza) 
and how it affects the qi of the body, otherwise referred to as `energy’, was noted in the 
ancient text Shen Nong Ben Cao Jing.  The translated text states: `Salvia is bitter and 
slightly cold.  It is non-toxic, treating mainly evil qi in the heart and abdomen, continual 
gurgling of the intestines like water running, cold and heat, and gatherings and 
accumulations.  It breaks concretions and eliminates conglomerations, relieves vexatious 
fullness, and boosts the qi (Mdidea 2010)’. 
 
The more recent materia medica of CHM list Danshen as a commonly used herb indicated 
for its ability to invigorate the blood and break up blood stasis, clear heat and soothe 
irritability (Bensky 1986). 
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1.1.4.2  Danshen and Danshen related products 
Danshen has been used as part of various patent CHM’s, particularly in treatment of 
cardiovascular disease.  Notably, the compound Danshen dripping pill (DDP) has been 
well used and documented for prevention and treatment of cardiovascular disease in China.  
DDP consists of active herbal ingredients extracted from Salvia miltiorrhiza, 
Panaxnotoginseng and Cinnamomuma Camphora.  A recent meta-analysis of randomised 
controlled trials from Medline and China National Knowledge Infrastructure database was 
performed during the period from 1966-2010 to compare the compound DDP with 
isosorbide dinitrate (ID), a conventional form of treatment for stable angina (Yafeng Li 
2011).  Results showed DDP improved symptoms more than ID treatment (93.4% vs. 
73.8%), suggesting DDP is an effective therapy option to treat stable angina.  DDP is the 
first TCM product approved for phase II and phase III clinical trails by the United States of 
America (USA) Food and Drug Administration (FDA) (Zhou, Zuo et al. 2005).    
 
Xie et al. (2000) demonstrated significant cardiovascular effects of Danshen containing 
tablets, Xiaoyu tablets.  Xiaoyu tablets is a compound preparation of CHM’s including 
Danshen extract containing 7.5% danchensu (danshensu) and protocatchuic aldehyde, and 
Shan Zha (Fructus Crataegi) extract containing 20% flavanoid components including 
hyperoside, vitexin, quercetin and rutine, that was shown to increase nitric oxide (NO) that 
strongly dilates blood vessels and decrease apoptotic nuclei in rabbit smooth muscle cells 
in atherosclerotic vessel walls (Xie, Mao et al. 2002).    
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Figure 1.4  Image of Danshen patent pills (left: compound Danshen dripping pill (DDP);  
 
middle: Dan Shen Pian Pill; right: Cardiotonic Pill). 
 
 
1.1.4.3  Chemical composition of Danshen 
Since the early 1930’s the chemical constituents of Danshen have been studied (Zhou, Zuo 
et al. 2005).  More than 70 compounds have been isolated and structurally identified from 
Danshen (Yong Guo Li 2009).  The main components of Danshen can be divided into two 
major groups, lipid soluble including tanshinones that consist of nearly 40 variants of the 
basic tanshinone structure found in the root of Danshen (Yong Guo Li 2009), and water 
soluble components including salvianolc acid A (SalA) and salvianolic acid B (SalB), 
danshensu (DSS) and caffeic acid and its’ derivatives.  There is a miscellaneous group of 
Danshen components that includes protocatechuic acid and protocatechuic aldehyde, 
usually used as a biomarker to evaluate the quality of Danshen and its’ pharmacological 
preparation (Suo, Qin et al. 2005; Liu, Li et al. 2006).   
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1.1.4.3.1 Lipid-soluble components 
The lipid-soluble compounds of Danshen that are not soluble in water include mainly 
tanshinones, which are the major bioactive constituents of Danshen, with unique chemical 
constituents not found in other CHM’s.  The structure of major tanshinones, tanshinone I 
(TanI), tanshinone IIA (TanIIA), cryptotanshinone (CT) and magnesium tanshinoate B 
(MTB) are shown in Figure 1.5.  Other tanshinones include tanshinone IIB, 15, 
16-dyhydrotanshinone I (15, 16-DTs1) and other tanshinones (Han, Fan et al. 2008).  The 
total tanshinone content of dried Danshen root is about 1%, with tanshinone I (TanI) , 
tanshinone II (TanII) and cryptotanshinone (CT) being present in largest amounts (Li, 
Wang et al. 2005).  
  
 14 
 
 
 
 
 
Tanshinone I      Tanshinone IIA               
 
 
 
 
 
 
Cryptotanshinone           Magnesium tanshinoate B  
 
Figure 1.5 Chemical structures of four bioactive tanshinones isolated from Danshen 
root 
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1.1.4.3.2 Water-soluble components 
Water-soluble compounds of Danshen that are capable of disolving in water include SalA, 
SalB, DSS, Rosmarinic Acid and Dimethyl lithospermate (See Fig. 1.6).  Of these, SalB 
has gained particular interest in its ability to act as an anti-oxidant (See Fig 1.6).  The 
chemical structure of major bioactive water soluble components is shown in Fig. 1.6. 
 
 
 
 
 
Salvianolic Acid A             Danshensu    
 
 
 
 
 
   
 Salvianolic Acid B 
 
 
 
Rosmarinic Acid       Dimethyl lithospermate 
Figure 1.6 Chemical structures of major bioactive water-soluble components isolated 
from Danshen root 
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1.1.4.4 Pharmacological activities of Danshen 
Pharmacological activities of Danshen have been widely studied in recent years.  There is 
strong evidence indicating the anti-oxidant properties (Jiang, Lau et al. 2005; Shiao, Chiu 
et al. 2008),  anti-inflammatory (Yagi and Takeo 2003), anti-cancer (Yuan, Wang et al. 
2003; Wang, Morris-Natschke et al. 2007), anti-microbial, anti-virus (Cui, Wang et al. ; 
Jiang, Lau et al. 2005) and cardiovascular activities of Danshen extracts and bioactive 
compounds in vitro and in vivo (Ji, Tan et al. 2000; Jiang, Lau et al. 2005; Zhou, Zuo et al. 
2005; Cheng 2007).   
 
It has been found that lipid-soluble and water-soluble components of Danshen have 
different pharmacological activities.  Lipid-soluble components have demonstrated strong 
ability in anti-tumor activity, anti-bacterial, anti-inflammatory, anti-immunological effects 
and cardioprotective activity (Wang, Morris-Natschke et al. 2007), whilst water-soluble 
components demonstrate relatively stronger anti-oxidant ability in addition to 
cardio-protective properties also demonstrated in lipid-soluble compounds  (Zhou, Zuo et 
al. 2005). 
 
The bioactivities of Danshen compounds may be related to their actions on cellular 
mechanisms.  For example, Chen (2009) showed compounds of Danshen, magnesium 
lithospermate B (MLB), magnesium lithospermate (ML) and sodium rosmarinate  to 
regulate calcium (Ca2+) homeostasis in vascular smooth muscle cells (Chen, Xuan et al. 
2009).  The water-soluble compound, SalA has been demonstrated to prevent 
ischaemic-reperfusion injury-induced myocardial damage by reducing necrosis and 
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apoptosis in isolated rat hearts and cardiomyocytes (Chan, Pannangpetch et al. 2000), 
whilst Ren et al. (2010) demonstrated TanIIA to attenuate inflammatory responses of rats 
with myocardial infarction by reducing inflammatory responses (Ren, Tong et al. 2010).  
However, in many other aspects the mechanisms of actions of Danshen are still not clear. 
 
1.1.4.4.1 Pharmacological actions of lipid-soluble components 
TanIIA has been demonstrated to have strong anti-tumor activity as it possesses cytotoxic 
activity and induces differentiation and apoptosis (Lee, Cheung et al. 2010 ; Wang, 
Morris-Natschke et al. 2007; Liu, Zhang et al. 2009; Lu, Zhang et al. 2009). 
 
TanI, TanIIA, and dihydrotanshinone I (DTanI) exhibit strong anti-fungal activity, whilst 
CT and DTanI have been demonstrated to possess strong anti-bacterial activity and inhibit 
a range of gram-positive bacteria (Wang, Morris-Natschke et al. 2007).   
 
Compounds including TanI, CT and TanIIA have all been demonstrated to inhibit 
inflammatory and immunological pathways (Kang, Chung et al. 2000; Jang, Jeong et al. 
2003; Jin, Yin et al. 2006).  Kang et al. (2000) demonstrated all three compounds to also 
inhibit interleukin-12 and interferon-gamma production in immune cells that activate 
inflammation.  Jin et al. (2006) demonstrated CT to inhibit cyclooxygenase-2 enzyme 
activity suggesting anti-inflammatory activity, whilst Jang et al. (2003) demonstrated 
TanIIA to possess immunological benefit by inhibiting lipopolysaccharide-induced 
nuclear factor-kappa B (NF-Kappa B) activation in mouse leukaemic monocyte 
macrophage cells and regulate the immune responses. 
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Cardiovascular protective activity of tanshinones has been well demonstrated (Han, Fan et 
al. 2008).  Zhou et al. (2005) demonstrated CT to inhibit endothelin-1 expression and 
stimulate NO production in human vascular endothelial cells (HVEC) that supports 
vasodilatation (Zhou, Wang et al. 2006).  TanIIA was also demonstrated to possess 
protective effects on human umbilical vein endothelial cells (HUVEC) injured by 
hydrogen peroxide (H2O2), that is involved in decreasing the viability of cells to induce cell 
apoptosis (Lin, Wang et al. 2006).  Furthermore, TanIIA has demonstrated strong effect 
on increasing NO production in HVEC that result in increased vessel dilatation (Huang, 
Wang et al. 2007)   Furthermore, MTB was shown to have inhibitory effects of 
stress-activated protein kinase in the ischaemic/ reperfused heart, that is understood to lead 
to cardiomyocyte death (Au-Yeung, Zhu et al. 2001).     
 
1.1.4.4.2 Pharmacological actions of water-soluble components 
Water-soluble components of Danshen have been demonstrated to possess strong 
anti-oxidant ability (Huang and Zhang 1992) and immune regulatory actions (Abd-Elazem, 
Chen et al. 2002) as well as cardio-protective effects (Nie, Xia et al. 2007; Han, Fan et al. 
2008).  Among these, SalB and DSS have been well studied.  Both compounds have been 
demonstrated to have anti-oxidant properties by scavenging free radicals in HUVEC 
(Zhao, Zhang et al. 2008) with protective effects from oxidative injury against radicals 
including superoxide (O2
-), H2O2 and hydroxide (OH
-).   
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Kang et al. (2002) investigated the effects of water-extracts of Danshen on the angiotensin 
converting enzyme (ACE) activities, systolic blood pressure (SBP) and hormone levels in 
plasma of rats, namely renin involved in the pathophysiology of hypertension.  ACE was 
inhibited by the addition of Danshen water extract in a dose-dependent manner and SBP 
was also decreased significantly, whereas plasma renin activity was not altered (Kang, Yun 
et al. 2002). 
 
MLB demonstrated strong O2
- radical scavenging and xanthine oxidase (XO) inhibitory 
activity in vitro suggesting a role in the anti-inflammatory processes such as gouty 
inflammation whereby an over production of XO is accumulated (Liu, Chen et al. 2009). 
 
As the developing body of research suggests, Danshen affects a variety of actions 
including the strong role it has demonstrated to play in inflammatory conditions, however 
the exact mechanisms of its’ actions is not clear.  Determination of the effects of Danshen 
extracts and compounds in the important role of O2
- production and inflammation in 
vascular endothelial tissue may provide insight into treatment for vascular disease.    
 
 
1.1.4.5 Clinical application of Danshen 
Danshen has been demonstrated to possess a wide application of therapeutic benefits but 
specifically known for its’ various cardio-protective mechanisms (Cheng 2007).  
Danshen has been demonstrated to dilate coronary arteries (Lei and Chiou, 1986), 
increase coronary blood flow and scavenge free radicals in ischaemic diseases (Nie, Xia 
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et al. 2007, Yang et al. 2009).  Danshen appears in numerous clinical formulations, 
often as a key ingredient or adjunct herb (Zhao, Gaudry et al. 2008).  Additionally, 
Danshen is also used singularly in injectable form for intravenous administrations in 
China for cardiovascular, diabetic and hepatic disease (Ye, Liu et al. 2005; Zhang, Li et al. 
2005; Lin, Hsu et al. 2008).  Other clinical applications of Danshen include pancreatitis, 
chronic renal failure, inflammation and neurodegenerative diseases (Wang and Xu 2005; 
Pu, Yang et al. 2006; Yue, Lee et al. 2006; Wu, Qiao et al. 2007; Wu, Wen et al. 2007; You, 
Pan et al. 2007; Cho, Cho et al. 2009).  A number of randomised double-blind placebo 
controlled studies of Danshen have been conducted (See Table 1.1). 
 
Danshen is taken routinely by many individuals in China for treatment of cardiovascular 
disease.  However, it is advised that caution and/ or avoidance of taking Danshen and 
other herbal medicines in conjunction with cardiovascular pharmacotherapy, namely 
warfarin, due to possible over-anticoagulation and other complications (Wu and Yeung ; 
Chan 2001; Izzo, Di Carlo et al. 2005).  Danshen has been demonstrated to strongly 
inhibit platelet aggregation and reported to potentiate the blood thinning effects of 
warfarin, hence should be avoided in patients with bleeding disorders, prior to some 
surgical procedures or when taking anti-coagulant (blood thinning) drugs, herbs, or 
supplements (Wang 2010).  
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Table 1.1  
Selection of randomised double-blind, placebo-controlled studies of Danshen 
 
Danshen, Danshen & other    Disease/ Syndrome      Reference 
CHM, Danshen compounds 
___________________________________________________________________________________________________________ 
 
Danshen    Chronic Fatigue Syndrome    (Cho, Cho et al. 2009) 
 
Danshen    Nasopharangeal Carcinoma    (Bao, Wong et al. 2006) 
 
Lyophilized Salvia Salt    Coronary Heart Disease-     (Zhang, Liu et al. 2006) 
(Lithospermic Acid)    Angina Pectoris 
 
Danshen     Immunomodulatory      (Wong, Tse et al. 2004)   
& Yun Zhi    effects  
 
Danshen    Myocardial damage postoperative   (Xia, Gu et al. 2003) 
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1.2 Vascular disease and ROS 
Vascular disease is a condition that affects the blood vessels.  Vascular disease is largely 
caused by hardening of the arteries and is referred to as atherosclerosis (Herrmann, Lerman 
et al. 2010 ; Libby, Ridker et al. 2009).  Atherosclerosis is due to a thickening of the artery 
lining from fatty deposits or plaques called atheroma.  The arteries that supply blood, 
oxygen and nutrients to the body from the heart are narrow and hardened in atherosclerotic 
conditions as a result and thus make it more difficult for blood and essential nutrients and 
gases to flow through and reach the tissues (Herrmann, Lerman et al. 2010).  Those parts 
of the body most affected by this disease suffer the consequence of an inadequate blood 
supply, poor function, tissue damage and in worst cases, necrotic cell death.  Vascular 
disease most commonly affects the arteries of the heart, brain and legs and is referred to as 
cardiovascular disease, cerebrovascular disease, and peripheral vascular disease, 
respectively.   
 
 
1.2.1 Vascular disease and oxidative stress 
The pathogenesis of vascular disease links closely with oxidative stress.  Oxidative stress 
is largely caused by an imbalance between the activity of endogenous pro-oxidative 
enzymes such as nicotinamide adenine dinucleotide phosphate-oxidase (NADPH Oxidase) 
or XO and anti-oxidant enzymes such as SOD, glutathione peroxidase and heme 
oxygenase (Forstermann 2008).  Oxidative stress is understood to be a common 
denominator in many aspects of cardiovascular disease (Inagi 2006; Misra, Sarwat et al. 
2009).  More specifically, various reactive oxygen species (ROS), including NADPH 
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oxidase are thought to play a key role by down-regulating NO, responsible for 
vasodilatation and reducing platelet adhesion involved in cardiovascular disease (Zhang, 
Huo et al. 2009).  A novel approach to target such enzymes may prove beneficial in the 
treatment of cardiovascular disease.  
 
1.2.2 Vascular disease and endothelium dysfunction 
Vascular disease is a pathological state within the arteries triggered by endothelial 
dysfunction (Libby, Ridker et al. 2009).  A single layer of endothelial cells line the inner 
surface of the entire vascular system and is understood to be implicated in vascular disease.  
Studies have demonstrated that endothelial cells control vascular homeostasis and are 
directly involved in cardiovascular disease.   
 
Endothelial dysfunction involves the pathogenesis of vascular oxidative stress resulting in 
increased production of ROS that contribute to vascular dysfunction.  Endothelial 
dysfunction is understood to be a shift of the actions of the endothelium toward reduced 
vasodilatation, a pro-inflammatory state, and pro-thrombotic properties (Endemann and 
Schiffrin 2004; Tesfamariam and DeFelice 2007).   
 
Endothelial dysfunction has been implicated in the pathophysiology of most forms of 
vascular and cardiovascular disease including hypertension, coronary artery disease, 
peripheral artery disease, diabetes, chronic heart failure and chronic renal failure 
(Endemann and Schiffrin 2004; Tesfamariam and DeFelice 2007). 
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It is understood that various risk factors, including dyslipidaemia, hypertension, diabetes 
mellitus and cigarette smoking have been shown to play a role in vascular endothelial 
dysfunction (Muzaffar, Shukla et al. 2005; Pongnimitprasert, El-Benna et al. 2008).   Risk 
factors are responsible for the increased production of inflammatory mediators, including 
cytokines and eicosanoids, leading to an increase in enzymatic activity involved in 
inflammatory condition within the endothelium (See Fig. 1.8). 
 
Vasodilator substances produced by the endothelium include NO, prostacyclin, various 
endothelium-derived hyperpolarising factors and C-type natriuretic peptides.  
Vasoconstrictors include endothelin-1, Ang II, thromboxane A2 and ROS.  The 
inflammatory modulator NO is well documented, in addition to other such inflammatory 
modulators including intercellular adhesion molecule-1, vascular adhesion molecule-1, 
E-selectin and NF-kB (Endemann and Schiffrin 2004; Tesfamariam and DeFelice 2007).  
In particular, NO is a potent endogenous inhibitor of blood cell adhesion and is a 
vasodilator which reduces the promotion of inflammation (Muzaffar, Shukla et al. 2005).   
 
1.2.3 Role of ROS in cardiovascular disease 
ROS are chemically-reactive molecules containing oxygen.  ROS are derivatives of 
cellular metabolism found in all biological systems (Touyz and Schiffrin 2004).  Limited 
amounts of ROS are beneficial in immune defence and cell signalling within cells 
(Massaad and Klann 2011).  However, an imbalance between the production of ROS 
produced by reactive oxygen, and the body’s ability to detoxify the reactive intermediates 
leads to what is referred to as oxidative stress, which can result in significant cell damage.  
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Oxidative stress is one of the key mechanisms involved in cardiovascular disease.  ROS 
can lead to impairment of endothelial-dependent vasodilatation which plays a significant 
role in modulation of vasoconstrictive activity in the vasculature.  NADPH-oxidase 
derived O2
- productions have also been involved in cardiac and vascular dysfunction in 
genetically obese and hypoglycaemic rats (Serpillon, Floyd et al. 2009).  
 
1.2.4  Source of ROS in vascular disease 
O2
- is a major source of ROS produced by various enzymes including NADPH oxidase, 
XO, nitric oxidase synthase (NOS), arachidonic acid metabolising enzymes, 
intramitochondrial oxidases, cytochrome P-450 enzymes, phagocytic myeloperoxidase 
system, lipoxygenase and cyclooxygenase (Munzel, Sinning et al. 2008).  Under 
physiological conditions, where the concentration of O2
- is low and the concentration of 
SOD is high, an enzyme that catalyzes the dismutation of O2
- into oxygen (O2) and H2O2, 
the less reactive and more stable ROS, H2O2, will be formed  (Touyz and Schiffrin 2004).  
H2O2 is produced via anti-oxidative and anti-inflammatory pathways (Lin, Wang et al. 
2006).  O2
- and NO also react to form another oxidant peroxynitrite (ONOO-) that is 
harmful to the vasculature.   
 
NADPH oxidase constitutes as the primary source of O2
- in endothelial and vascular cells 
and whose primary function is ROS generation (Berry, Hamilton et al. 2000; Muzaffar, 
Jeremy et al. 2003; Touyz and Schiffrin 2004; Zalba, Beloqui et al. 2005; Dworakowski, 
Alom-Ruiz et al. 2008).  It has also been the most widely studied enzymatic source of O2
- 
in the vascular wall (Loomis, Sullivan et al. 2005).   
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Figure 1.7 (below) shows NADPH oxidase enzymes (NOX) in the vascular wall.  All 
three layers of the vascular wall, intima containing endothelial cells, media containing 
smooth muscle cells and adventitia containing fibroblasts and macrophages express NOX 
family members.  NOX 4 is the predominant isoform in endothelial cells, NOX 1 and 
NOX 4 in smooth muscle cells, NOX 4 in fibroblasts and NOX 2 in macrophages (Bedard 
and Krause 2007).     
 
 
 
Figure 1.7 NOX enzymes in the vascular wall. (Bedard and Krause 2007) 
 
NADPH oxidase is an enzyme that catalyses the production of O2
- from O2 and NADPH. 
The intravascular formation of O2
- is mediated largely by the abnormal activity and 
expression of NADPH oxidase due to risk factors associated with inflammatory conditions 
and hypoxic conditions of the vasculature (See Fig. 1.8 below).  The NADPH oxidases of 
the cardiovascular system are membrane associated multi-subunit enzymes which contain 
multiple protein isoforms: p47phox, p67phox, gp91phox, p22phox and RAC proteins.  
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NADPH oxidase is a major cause of atherosclerosis and inflammation, understood to be 
one of the key mechanisms involved in oxidative stress in vascular disease (Frey, 
Ushio-Fukai et al. 2009).   
 
 
 
Figure 1.8 Model of pathogenic events leading to increased superoxide (O2
-) 
expression in vascular tissue (modified from (Muzaffar, Shukla et al. 2005; 
Pongnimitprasert, El-Benna et al. 2008)). 1) Risk factors promote adhesion of blood 
cells to endothelium.  These release factors that up-regulate NADPH oxidase and xanthine 
oxidase expression.  Both enzymes increase superoxide (O2
-), hydrogen peroxide (H2O2) 
formation; 2) O2
- promotes inflammation and vasoconstriction and reduces nitric oxide 
(NO) derived from endothelial nitric oxide synthase (eNOS) to form reactive nitrogen 
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species (RNS), including peroxynitrite (ONOO-); 3) NO also suppresses NADPH oxidase, 
further promoting NADPH oxidase expression and activity; 4) O2
- itself induces NADPH 
oxidase expression, thus increasing O2
- by a self-amplifying loop; 5) Such events may lead 
to tissue hypoxia which also up-regulates NADPH oxidase expression  
 
Various risk factors promote the adhesion of blood cells to the endothelium followed by the 
release of factors including cytokines and eicosanoids that regulate the expression of 
NADPH oxidase and increase the formation of O2
-.  O2
- promotes inflammation and 
vasoconstriction in its own right, but also reduced NO derived from endothelial Nitric 
Oxidase Synthase (eNOS) to form reactive nitrogen species (RNS) including peroxynitrite 
(ONOO-) will lead to inflammation and vasoconstriction.  NO is a potent endogenous 
inhibitor of blood cell adhesion activity and a potent vasodilator, thus its reduction results 
in inflammation and hypertensive effects of O2
-.  NO also suppresses the expression of 
NADPH oxidase, this reduction of NO further results in NADPH oxidase expression and 
activity.  O2
- itself induces the expression of NADPH oxidase, thereby increasing O2
- 
formation.  These inflammatory events may lead to tissue hypoxia, which also up-regulate 
the expression of NADPH oxidase (Muzaffar, Shukla et al. 2005).  Potent inhibitors of 
NADPH oxidase such as synthetic compound diphenyleneiodonium (DPI), along with 
anti-oxidants dismantle the adhesion and allow the macrophages to migrate out from the 
intima of the artery wall (Park, Febbraio et al. 2009).  Many studies now suggest that 
various plant-derived substances are beneficial in the inhibition of O2
- including many 
CHM’s that act as anti-oxidants (Zhu, Huang et al. 2004).  Thus, specifically targeting 
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enzymes responsible for O2
- production may prove beneficial in the treatment of 
inflammation involved in cardiovascular disease. 
 
1.2.5 Anti-oxidant therapies 
Various anti-oxidant reagents have been considered as potential drugs for treating 
cardiovascular disease (Inagi 2006).  Drugs in current use for cardiovascular disease, 
specifically hypertension, include ACE inhibitors and angiotensin receptor blockers 
(ARB) and anti-hyperlipidemic reagents like statins.  These drugs protect various organs 
via anti-oxidative stress effects in addition to their original pharmacological properties.  
Inhibitors of XO and NADPH oxidase, which regulate intracellular redox reaction of 
oxidative stress may be considered for possible future treatment in cardiovascular disease 
(Inagi 2006). 
 
Many drugs used in cardiovascular medicine have shown to influence NADPH oxidase 
expression and activity (Muzaffar, Shukla et al. 2005).  Such drugs include NO donors, 
nitroaspirin, corticosteroids and other specific inhibitors (Muzaffar, Shukla et al. 2005).  
 
It has been suggested that targeted therapeutic strategies of enzymes involved in 
cardiovascular disease such as NADPH oxidase, rather than non-specific anti-oxidant 
approaches that to date have been disappointing in clinical trials, may prove worthwhile 
(Seddon, Looi et al. 2007).  Further studies are needed to develop more specific NADPH 
oxidase inhibitors.  A natural organic compound, apocynin, that has been isolated from a 
variety of plant sources, was initially thought to target NADPH oxidase directly (Muzaffar, 
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Shukla et al. 2004; Muzaffar, Shukla et al. 2005), however later evidence indicate that it is 
not a specific NADPH oxidase inhibitor in vascular systems (Heumuller, Wind et al. 2008).  
Currently, there are various novel NADPH oxidase inhibitors that are under development 
(Spychalowicz et al. 2012; Drummond et al. 2011).   
 
1.2.6 ROS detection and quantification 
Numerous methods have been developed for ROS detection and quantification.  For 
example, methods to quantify O2
- include cytochrome C reduction, 
chemiluminescence-based techniques, electron spin resonance (ESR), dihydroethidium 
and high-performance liquid chromatography (Dikalov, Griendling et al. 2007; Dikalov, Li 
et al. 2007).   
 
Reduction of cytochrome C is a preferred method of quantification of O2
- generation in 
large amounts by neutrophils or isolated enzymes.  However, for tissues such as vessels, 
vascular smooth muscle cells, endothelial cells and samples of cardiac tissues, the level of 
O2
- produced is much lower.  ESR is a preferred method when studying isolated enzymes 
due to it’s precision in product formation and it’s intermediates, however this technique has 
certain limitations for intact tissues or cells and is very expensive requiring large amounts 
of location space (Dikalov, Griendling et al. 2007).  However, more recent studies have 
successfully used ESR in vivo to determine oxidative stress (Yakugaku 2008; Cai, Dikalov 
et al. 2007). 
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Detection of O2
- with dihydroethidium and high performance liquid chromatography is 
preferred methodology for detection over other such methods including cytochrome C 
assay as it is able to detect intracellular O2
- production (Dikalov, Griendling et al. 2007). 
 
Chemiluminescence-based techniques have been widely used as they are inexpensive and 
can be used with equipment commonly available in laboratories.  These techniques 
involve using chemiluminscent probes which release a photon when exposed to O2
- and 
detected by a luminometer.  As the compounds are cell permeable, the O2
- measurement 
reflects both extracellular and intracellular production.  The most commonly used 
technique for O2
- measurement is the lucigenin-enhanced chemiluminescence technique 
(Dikalov, Griendling et al. 2007). 
 
The lucigenin-enhanced chemiluminescence assay is a preferred method as the 
lucigenin-enhanced chemiluminescence signal is well within the linear range of 
pathological samples.  Normal tissue samples do produce low levels of O2
- however such 
readings are only slightly above background readings.  The validity of lucigenin-enhanced 
chemiluminescence has been questioned due to the possibility of O2
- production being 
overestimated due to the redox-recycling phenomenon, whereby the lucigenin radical can 
react with oxygen to generate O2
- (Dikalov, Griendling et al. 2007).  However, when 
5µmol/L of lucigenin is used, the amount of artefact is likely to be insignificant (Van Dyke, 
Patel et al. 2003).  The lucigenin assay used to measure O2
- production is understood to 
provide excellent quantification and reproducibility (Van Dyke, Patel et al. 2003), and is 
understood to be reliable (Afanas’ev 2001).   
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Detection of non-specific inhibition of ROS in vitro using lucigenin enhanced 
chemiluminescence assay using the xanthine-xanthine oxidase system is a well utilised 
system.  Chemiluminescence is widely used for the determination of ROS including O2
-, 
H2O2 and OH
-.  This method is mainly used for in vitro detection of ROS.  Lucigenin is 
used to amplify chemiluminescence intensity that otherwise would normally be very weak 
and requires highly sensitive equipment (Wilhelm and Vilim 1986).  Xanthine-xanthine 
oxidase system is widely used as a model system for chemiluminescence measurements in 
cell free systems.  This model system produces both H2O2 and O2
- as primary products 
after oxidation of various substrates, hence it is not possible to evaluate the contribution of 
individual ROS by measurement of chemiluminescence only (Wilhelm and Vilim 1986).  
For detection of specific ROS in vascular tissue, namely NADPH oxidase, this can be 
determined by lucigenin-enhanced chemiluminescence assay. 
 
1.3 CHM for vascular disease 
Various Chinese herbs have been used for treating vascular disease.  Such Chinese herbs 
including Danshen and Ge Gen (Radix Puerariae), have demonstrated vasorelaxant effects 
in occlusive cerebrovascular disease (Lam, Deng et al. 2010).  Panaxnotoginsenosides 
found in ginseng (Panax Ginseng) has been demonstrated to prevent atherosclerosis (Liu, 
Wang et al. 2009).  Ginkoglide B from the herb Ginko Biloba, has been demonstrated to 
inhibit inflammation processes in HVEC (Li, Chen et al. 2009).  Huang Qi (Astragalus 
Membranaceus var. Mongholicus) and Dang Gui (Angelica Sinensis) have both been 
demonstrated to improve renal microvascular insufficiency (Song, Meng et al. 2009).  A 
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Chinese medicine capsulated herbal formula, Tongxinluo, used in angina pectoris and 
ischemic stroke in China was demonstrated to be as effective as the commonly used drug, 
Simvastatin, a cholesterol lipid lowering drug used to lower serum lipid levels, inhibit 
plaque inflammation and prevent vulnerable plaques from rupture (Zhang, Wu et al. 2008; 
Chen, Zhong et al. 2009).    
 
1.3.1 CHM & vasodilatation 
Various CHM’s have been demonstrated to produce vasodilatation effects beneficial in 
vascular disease (Lam, Deng et al. 2010).  The Chinese herbal extract Ziziphora 
clinopodiodes Lam (Lamiaceae) was demonstrated to induce vasorelaxation in rat thoracic 
aorta mediated by inhibition of extracellular calcium (Ca2+) influx (Senejoux, Girard et al. 
2010) as has Scutellarin (Pan, Feng et al. 2008).  Xanthoceras sorgbifolia extracts were 
demonstrated to relax smooth muscle in rat thoracic aortic ring via endothelial dependent 
NO cyclic guanosine monophosphate (cGMP) signalling, a major pathway for endothelial 
vascular relaxation (Jin, Wen et al. 2012).   
 
A number of Chinese herbs have been demonstrated to have vasodilatory effects via the 
NO pathway, an important signalling molecule involved in a diverse range of 
physiological functioning and disease.  Such Chinese herbs include Zizyphi Spinosi 
semen (Liu, Chen et al. 2007; Steinkamp-Fenske, Bollinger et al. 2007),  Astrogalus 
zahlbruckneri (Navarrete, Arrieta et al. 2005), Buxus microphylla (Hu, Liu et al. 2007), 
Evodia rutaecarpa (Chiou, Sung et al. 1997; Zhao, Zhou et al. 2009), Aconittum coreanum 
(Pyo, Kim et al. 2007; Pyo, Lee et al. 2008), Radix Stephania tetrandra (Kwan, Ma et al. 
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1999; Kwan and Achike 2002), Hyoscyamuse niger (Luo and Zhou 2009), Coptidis 
rhizome & Phellodendri cortex (Lin, Yang et al. 2008; Thirupurasundari, Padmini et al. 
2009; Ye, Fu et al. 2009), Piper puberillum (Soliman and Mazzio 1998), Stephania 
cepharantha (Kondo, Ishiguro et al. 1993; Kondo, Takano et al. 1993) and Artemisia 
annua L. (Tang 1992).  These Chinese herbs may be useful in treating cardiovascular 
diseases associated with impairment of NO function. 
 
1.3.2 CHM & ROS inhibition 
A number of CHM’s have been well demonstrated to have ability to inhibit ROS 
production via inhibition of NADPH oxidase (Zhu, Huang et al. 2004; Chang, Ding et al. 
2008; Liao, Banbury et al. 2008).  Panax ginseng, P. notoginseng and Ligusticum chuan 
xiong all down-regulated expression of NADPH oxidase subunits in HUVEC (Yang, Lei et 
al. 2009).  Certain active compounds of CHM, such as evodiamine and rutaecarpinine 
have demonstrated to suppress NADPH oxidase activation (Heo, Yun et al. 2009). 
  
1.3.3 Anti-oxidant actions of Danshen and NO pathway 
Danshen is an important herb used extensively in China primarily for treatment of 
cardiovascular disease including angina pectoris and myocardial infarction, in addition to 
haemorrhage, dysmenorrhea, miscarriage, insomnia and various inflammatory and 
neurodegenerative diseases (Wang, Morris-Natschke et al. 2007).  Danshen has also been 
well documented to have anti-oxidant potential from inhibition of ROS (Zhou, Zuo et al. 
2005; Han, Fan et al. 2008).  Various compounds isolated from Danshen have been 
demonstrated to have effect on vascular endothelium (See Fig. 1.9). 
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Research has demonstrated Danshen lipophilic and hydrophilic compounds, namely 
3,4-dihydroxyphenyl lactic acid (DLA), SalB, TanIIA, Isotanshinone IIB (ITSIIB), CT, 
MTB and ursolic acid (both water-soluble and alcohol-soluble), modulate endothelium 
derived vasodilators to promote vasodilatation, thus minimising endothelial dysfunction.  
This action of Danshen may explain its’ clinical efficacy seen in various cardiovascular 
disease states however its’ mechanisms of action are still yet to be elucidated.   
 
More than 20 phenolic acids from water-soluble constituents from Danshen have been 
identified to demonstrate increase in NO production.  The compound MTB was found to 
increase NO in HVEC at concentrations of 2.5mg/L, 5mg/L and 10 mg/L with eNOS 
mRNA expression increased and inducible Nitric Oxide Synthase (iNOS) and messenger 
Ribonucleic Acid (mRNA) expression decreased, suggesting possible selective actions on 
different Nitric Oxide Synthase (NOS) enzymes (Luo, Dong et al. 2002).  The lipophilic 
abietane type-diterpene quinine pigments in Danshen, including TanIIA, 15,16-DTsI and 
CT have also been demonstrated to also affect NO pathway with anti-bacterial, 
anti-oxidant, anti-inflammatory, and anti-neopastic actions (Wang, Morris-Natschke et al. 
2007).  TanIIA was demonstrated to induce NO production significantly in HUVEC by 
fluorescence assay at concentrations of 100 µM (Huang, Wang et al. 2007).   
 
A study by Kim et al (2007) demonstrated that TanIIA targeted eNOS as a signaling 
element in HVEC (ECV-304) cells by increasing total level of eNOS and 
phosphorylated-eNOS.  This may provide explanation for reduction of experimental 
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renovascular hypertension in hamsters, increased production of NO and induced 
vasodilatation in hamster cheek pouch arterioles (Kim, Sanchez et al. 2007). 
 
Zhou et al. (2006) demonstrated that CT significantly increased eNOS but not neuronal 
Nitric Oxide Synthase (nNOS) in HUVECs, thus acting in a specifically targeted manner 
(Zhou, Wang et al. 2006).  Importantly, activation of iNOS results in large amounts of NO 
over a long period of time, with excessive production understood to be neurotoxic (Suarez, 
Bodega et al. 2005) and implicated in the pathogenesis of a number of nervous system 
diseases (Suarez, Bodega et al. 2005).  Thus, if Danshen is able to target specific NOS, 
this would be therapeutically beneficial.  MTB has been demonstrated to stimulate 
production of NO in ECV304 via eNOS at concentrations of 1-10 µM with increased NOS 
activity and expression of eNOS proteins (110-178%) (O, Cheung et al. 2000).  This 
suggests possible selective activation of eNOS by MTB.   
 
Steinkamp-Fenske et al. (2007) demonstrated ursolic acid, a water-soluble compound 
extracted from Danshen, to up-regulate eNOS and down-regulate Nox4 expression in 
human endothelial cells (Steinkamp-Fenske, Bollinger et al. 2007).  Up-regulation of 
eNOS and down-regulation of NOX 4 can lead to a decrease in O2
- production and increase 
in NO that promotes vasodilatation and relaxation.  According to Steinkamp-Fenske et al. 
(2007) both hydrophilic and alcohol-soluble, but no lipophilic constituents of Danshen 
seem to be responsible for the eNOS up-regulating effect.   
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Additionally, Soung et al (2003) demonstrated specific ONOO- scavenging activity of 
lithospermate B (LSB) that promotes cellular defence activity in the protection against 
ONOO- involved diseases (Soung, Rhee et al. 2003).  Kim et al (2010) demonstrated 
Danshen compounds tanshinone, CT and 15, 16-DTsI to have antioxidant properties by 
inhibiting the ROS peroxy radical (Kim, Kwon do et al. 2010). 
 
 
1.4  Clinical application of Danshen 
 
1.4.1  Clinical application of Danshen in vascular disease 
Danshen is known for its’ clinical efficacy in treatment of vascular disease and has been 
tested in clinical trials (Zhang and Wang 2006) although exact mechanisms involved 
remain unclear (Park, Lee et al. 2008; Zhao, Zhang et al. 2008).  One of the most 
frequently used clinical applications of Danshen in China is treatment for manifestations of 
coronary artery disease including angina pectoris, coronary artery spasm and myocardial 
infarction (Cheng 2007).  Numerous clinical trials have demonstrated certain Danshen 
products to be effective and safe for treatment of angina pectoris, hyperlipidemia and 
ischaemic stroke (Ji, Tan et al. 2000; Zhou, Zuo et al. 2005).  Additionally, Danshen 
amongst various other Chinese herbs have been evaluated in the treatment of ischaemic 
stroke (Wu, Liu et al. 2007).   
 
Although there have been many clinical studies on Danshen, most of them are poor quality 
(Bo et al. 2008), thus it has been suggested that more evidence from high quality trials is 
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needed to support the clinical use of Danshen for treatment of clinical conditions such as 
acute myocardial infarction (Wu, Ni et al. 2008) and stroke (Wu et al. 2008). 
 
1.4.2 Danshen & ROS inhibition 
Danshen and its’ active compounds have been demonstrated to have anti-oxidant potential 
via the inhibition of ROS.  Compounds including DLA, SalB, TanIIA and CT have all 
shown affects to inhibit ROS (Han, Fan et al. 2008).   
 
There have been numerous studies demonstrating the protective effect of TanIIA, 
particularly in cardiovascular disease and hepatic disease (Yin, Kim et al. 2008; Park, Zhao 
et al. 2009; Wu, Zhou et al. 2009; Xu, Yang et al. 2009), which is associated with its’ 
actions on ROS inhibition.  Lin et al. 2006 demonstrated TanIIA to have protective effects 
on HUVEC injured by H2O2 (Lin, Wang et al. 2006).   
 
Kim et al. (2008) demonstrated DML to scavenge ONOO- efficiently and be potentially 
useful in the prevention of ONOO- related diseases such as Alzheimer’s disease, cancer, 
atherosclerosis and other inflammatory conditions (Kim, Kim et al. 2008).   
 
SalB has also been shown to have protective effects against oxidant stress by inhibition of 
ROS (Wang, Liu et al. 2009).  Wang et al. (2009) and Zhao et al. (2008) demonstrated 
both SalB and DSS to have strong antioxidant ability.  More specifically, Zhang et al 
(2006) reported SalB to produce dose-dependent decrease in ROS production and NADPH 
oxidase activity in human aortic smooth muscle cells (Zhang and Wang 2006).     
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Hydrophilic compounds of Danshen such as DSS and SalB, were demonstrated to have 
anti-oxidant properties by effectively scavenging free radicals in HUVEC (Zhao, Zhang et 
al. 2008).  These two natural phenolic acids of caffaic acid derivatives demonstrated 
protective effects from oxidative injury against O2
-, H2O2 and OH.  Both DSS and SalB 
exhibited higher scavenging activity against O2
- and OH than that of the well known 
antioxidant Vitamin C.  On the contrary, DSS and SalB showed weaker H2O2 scavenging 
activities than vitamin C (Zhao, Zhang et al. 2008).  
 
Various Danshen compounds have been shown to affect endothelial ROS and NO in vitro 
(See Table 1.2).  These include lipid and water-soluble compounds including DLA, SalB, 
TanIIA, ITsIIB, CTs, MTB and Ursolic Acid.  
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Table 1.2 
Compounds derived from Danshen and their actions on endothelial ROS and NO in vitro 
Compound Cells/Tissues   Effects           References                   
_________________________________________________________________________________________________________________________________ 
DLA HUVECs    Inhibit production of O2
-, H2O2       Guo et al., 2007 
 Xanthine-xanthine oxidase Inhibit O2
- production        Zhao et al., 1996 
SalB HASMCs    Inhibit ROS production        Zhang & Wang, 2006 
  Inhibit NADPH oxidase activity 
TanIIA HUVECs    Increase NO production        Lin et al. 2006 
 RAW 264.7    Increase NO production        Jiang et al., 2003  
 ECV 304    Increase eNOS expression       Kim et al. 2007 
ITsIIB Platelet     Inhibit platelet aggregation       Lee et al., 1987 
CTs HUVECs    Increase NO production 
 Increase eNOS expression        Zhou et al., 2006b 
MTB ECV 304        Increase NO production 
 Increase eNOS expression        Luo et al., 2002 
 ECV304        Increase NO level         O, Cheung et al., 2000 
Ursolic Acid EA.hy926        Increase NO production  
 Increase eNOS expression     Steinkemp-Fenske et al.  
     2007    
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Figure 1.9 Model of pathogenic events leading to increased superoxide (O2
-) 
expression in vascular tissue (modified from (Muzaffar, Shukla et al. 2005; 
Pongnimitprasert, El-Benna et al. 2008)) and possible targets by compounds 
derived from Danshen 
 
1.5  Quality assurance of CHM 
CHM’s are derived from nature, hence it is reasonable to expect their may be variation 
in bioactive components.  Clinical outcomes from the use of CHM’s are dependent 
on the quality and safety of herbs.  Efficacy of CHM’s due to inconsistent bioactive 
components of Chinese herbal raw materials may be reduced or cause significant 
adverse reaction (Sheng 2006).  CHM is often a decoction of a variety of Chinese 
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herbal raw materials which may contain many chemical components with varying 
amounts.  Thus, it is important to determine bioactive chemical components of 
individual CHM’s and possible interaction with other such herbs in controlled 
environments for assurance of quality control and clinical efficacy and safety.  Public 
belief that herbal and natural products are safer than synthetic medicines can only be 
ascertained by imposing regulatory standards on these products that involve chemical 
and biochemical analysis.  Herbs are derived from nature, thus the absorption of 
heavy metals from water or soil during growth must be additionally quantified and 
regulated to ensure quality assurance and reproducibility (Tomlinson, Chan et al. 
2000; Ernst 2002; Yuan, Koh et al. 2009). 
    
1.5.1 Australian grown Danshen  
The quality of imported raw herbs in Australia is not often properly assessed.  Due to 
the demand there have been efforts in growing Chinese herbs in Australia.  Recently, 
a field trial conducted at Royal Melbourne Institute of Technology (RMIT) reported 
successful cultivation of Danshen in Victoria (Li, Sheng et al. 2009).  This Australian 
field trial was initiated to determine the quality and safety of cultivation varieties of 
Danshen most suitable for local production in Australia.  The study demonstrated that 
high quality Danshen can be produced using proper procedures in determining 
selection of Danshen variety, harvesting time, fertilisation and plant density, however 
further validation is required (Sheng 2007).  Of the eight cultivated varieties in the 
study, seeds collected from Shangluo, Shanxi Province, were shown to produce a 
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moderate content of TanIIA (0.133%, w/w) and SalB (3.75%, w/w) in addition to a 
high root yield per square meter (325 g/plant-pair) (Sheng 2007).  Further studies on 
the actions of Australian grown Danshen may help to establish the quality and 
feasibility of using locally grown Danshen in CHM practice in Australia. 
 
1.6 Aims of Thesis 
Danshen has been well used and documented in the prevention and treatment of 
vascular disease, however the exact mechanisms of its’ actions is still not fully 
understood.  Given the critical role of ROS in vascular disease, it is important to 
study the actions of Danshen and its’ active compounds on ROS production.  
Additionally, understanding the bioactivity of locally grown Chinese herbs may help 
to promote the use of Australian grown raw materials in the practice of CHM in 
Australia.  Thus, it is important to study the actions of Australian grown Danshen 
(Guang Li, Jun Sheng et al. ; Sheng 2007; Li, Sheng et al. 2009; Li, Sheng et al. 2009). 
 
The major aims of this thesis are to determine the effectiveness of Danshen extracts 
and its main active compounds on ROS productions, in particular NADPH oxidase 
derived O2
-.  Danshen extracts used in the study were obtained from locally grown 
cultivation as mentioned above. 
 
 
 
  
 44
The specific aims of the study are to: 
1) Conduct a review on anti-oxidant actions of Danshen and Danshen active 
compounds and their effects on vascular functions 
2) Evaluate Australian grown Danshen extracts and active compounds on ROS 
production from xanthine xanthine-oxidase reaction in cell-free conditions 
3) Evaluate Australian grown Danshen extracts and active compounds on O2
- 
production, derived from NADPH oxidase in isolated rat aorta 
4) Conduct a review of clinical adverse reactions and drug reactions of 
Danshen 
 
The main research questions to be answered are:  
1) Are Danshen extracts and Danshen active compounds effective for 
scavenging ROS in cell free conditions? 
2) Are Danshen extracts and Danshen active compounds effective for 
inhibiting NADPH oxidase derived production of O2
- in vascular tissue? 
3) What are the possible adverse reactions and potential drug interactions of 
Danshen and its’ implications in clinical practice? 
 
This research may provide insight to understanding anti-oxidant actions of Danshen 
and potential application for treatment of vascular disease by use of locally grown 
Danshen materials. Additionally, understanding the safe use of Danshen may help to 
promote an evidence-based practice of CHM.
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Chapter Two 
 
 
Methodology 
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All experimental procedures completed in the study were performed in accordance to 
guidelines and specifications set by RMIT University Higher Degrees Committee and 
RMIT University Animal Ethics Committee, Melbourne, Australia (See Appendix 
7.1).    
 
2.1 Animals 
Male Sprague-Dawley rats (250g – 400g) were used in this study.  Rats were 
obtained from Monash Animal Services (Monash University, Clayton, Victoria) and 
housed at the Animal Facility (RMIT University, Bundoora, Victoria) on a 12 hour 
day/ night cycle at room temperature of 20 ± 2 °C.  The rats were fed rodent chow and 
water. 
 
2.2 Tissue Collection 
The rats were euthanized humanely by investigator.  Animals were deeply 
anaesthetised with Ketamine (60mg/kg) (Sigma-Aldrich) and Xylazine (8mg/kg) 
(Sigma-Aldrich) by intraperitoneal injection before aorta removed for experimental 
purposes.  The loss of foot pad and corneal reflexes were used to indicate deep 
anaesthesia.  The rat chests were then opened to isolate the descending thoracic aorta.  
After the removal of superficial connective tissue, the aorta was cut into ring 
segments, 2-3 mm long, and placed in ice-cold oxygenated Krebs-Hepes Buffered 
Saline (KHBS) solution (composition in mM: NaCl 119, KCl 4.7, MgSO4 1.17, 
NaHCO3 25, KH2PO4 1.18, CaCl2 2.5, glucose 5.5, EDTA 0.026, pH 7.4). 
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2.3 Lucigenin assay for ROS production by xanthine oxidase/ hypoxanthine in a 
cell free system 
 
2.3.1 Lucigenin assay for detection of ROS production in a cell-free system  
A chemiluminescence probe, lucigenin, emits light when reacting with O2
-.  The three 
reactions involved in the lucigenin-enhanced chemiluminescence (LC) are: 
 
Reaction 1: O2
- + LC2+ →LC+ + O2 
Reaction 2: LC+ + O2
-→LCO2     
Reaction 3: LCO2→2N-methylacridone+hv  
    (Dikalov, Griendling et al. 2007). 
 
O2
- reduces lucigenin (LC2+) to its cation radical (LC+).  This reacts with a second O2
- 
to form dioexetane molecule (LCO2) which emits light and detected by a microplate 
reader.   
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Fig. 2.1 FLUOstar OPTIMA Microplate  
 
2.3.2 Protocol for detection of ROS produced by xanthine oxidase/ hypoxanthine 
in a cell free system 
The assay was cell-free using 96-well plates covered with foil overnight prior to 
experiment to decrease light absorption.  On the day of the experiment 
Hepes-buffered Krebs (20mM HEPES, 128 mM NaCl, 2.5 mM KCl, 2.7 mM CaCl2, 
1mM MgCl2, 16 mM glucose, pH 7.4) and lucigenin were prepared, with 
Hepes-buffered Krebs solution used as a solvent for lucigenin.  A solution of 5 µM 
lucigenin was prepared and XO 0.01 U/ml final concentration was added into the 
solution, then 180 µl of the solution was added in triplicates into 96 white well plates.  
Triplicates were then treated with either 250 U/ml SOD, concentrations of Danshen 
extracts or compounds or no treatment as a control.  200 µl of 5 µM lucigenin were 
added in triplicates as background.  Finally, HX 100 µM was added to each well.  
All drugs and reagents were kept on ice until use during experiment and lucigenin 
preparations covered with foil until use.  The optiplate was read in the FLUOstar 
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OPTIMA Microplate reader (Fig.2.1) for 12 cycles at 5 seconds per well.  The 
average results of the 12 cycles were calculated. 
 
2.3.3 Lucigenin assay for detection of vascular superoxide (O2
-) 
NADPH oxidase is an enzyme that catalyses the production of O2
- from oxygen (O2) 
and NADPH, according to the following: 
 
NADPH + 2O2 →NADP+ + H+ + 2O2-  (Babior 2004). 
   
 2.3.4 Protocol for detection of vascular superoxide (O2
-) via lucigenin-enhanced 
chemiluminescence.   
Assay involved aortic rings using 96-well plates covered with foil overnight prior to 
experiment to decrease light absorption.  On the day of experiment, Hepes-buffered 
Krebs, diethyldithiocarbamic acid sodium salt (DETCA), β-nicotinamide adenine 
dinucleotide 2’-phosphate reduced tetrasodium salt hydrate (NADPH) and lucigenin 
solutions were prepared with Hepes-buffered Krebs solution also being used as a 
solvent for Danshen extracts and compounds.  Incubation solutions of 2 ml were 
prepared in 24-well plates, containing DETCA 3 mM and NADPH 100 µM, wash 
plates containing the same compounds minus DETCA were also prepared.  Aortic 
sections of 2-3mm in length from each rat were collected and placed in incubation 
plates, with sections from each rat being placed in incubation wells containing 
incubation solution with NADPH 100 µM and one without NADPH.  Another 
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section was also incubated with the NOX inhibitor diphyleneiodonium chloride (DPI).  
Additionally, concentrations of Danshen extracts or compounds were added to 
segment wells with a single well with no treatment as a control.  Plates were 
incubated at 37 °C for 45 minutes.   
 
During incubation period, the optiplate was prepared with 300 µl of 5 µM lucigenin 
with or without NADPH, DPI and Danshen extracts or compounds.  A background 
reading was performed using the FLUOstar OPTIMA Microplate reader (Fig.2.1) for 
12 cycles at 5 seconds per well. 
 
Following the 45 minute incubation period, aortic rings were washed in the wash 
plates and transferred into corresponding optiplate wells and Danshen extracts and 
compounds added accordingly.  The plate was then read again to establish production 
of O2
- content with aortic tissues.    
 
In order to determine NADPH oxidase derived O2
- content within tissues, the 
background (B) reading was subtracted from the final reading (R) and aortic rings 
were dried and weighed (W) and O2
- content calculated according to the following 
equation: 
 
ROS generated superoxide count (S) = R - B, superoxide content/mg = S/W 
S=R-B, superoxide content/mg = S/ W  
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2.4 Drugs and reagents 
Sigma Chemical Co, USA:  
Ketamine, Xylazine, NaCl, KCl, MgSO4, MgCl2, KH2PO4, NaHCO3, D-Glucose, 
Na-Hepes, CaCl2, Diethyldithiocarbamate (DETCA), nicotinamide adenine 
dinucleotide phosphate (NADPH), Lucigenin, diphenyliodonium (DPI), superoxide 
dismutase (SOD), xanthine oxidase (XO), hypoxanthine (HX). 
 
NICPCP, China: Danshen test compounds.    
 
2.4.1 Danshen extracts 
Aqueous and ethanol extracts of Danshen were prepared using materials attained from 
cultivated Danshen in the field trial in the City of Whittlesea, Victoria, Australia and 
extracted at RMIT University.  Danshen seeds from cultivar 4 were used in the 
experiments.  These seeds were obtained from Shangluo, Shanxi Province, China (Li, 
Sheng, et al. 2009).  
 
2.4.2 Drug preparation 
Drugs used were dissolved in distilled water (dH2O) or DMSO for making stock 
solutions.  Further diluations were made in Krebs’ solution (composition in mM: 
NaCl 119, KCL 4.7, MgSO4 1.17, NaHCO3 25, KH2PO4 1.18, CaCl2 2.5, glucose 5.5, 
EDTA 0.026, pH 7.4).  The relevant solvent (vehicle) controls were used for all 
experiments. 
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2.5 Statistical analysis 
Results are expressed as mean ± standard error of mean (S.E.M).  Number of 
experiments is denoted by n.  Evaluation of statistical significance between 
inter-group differences was conducted using Student’s paired t-test.  Differences 
between groups were considered to be statistically significant with probability (P) 
values <0.05.  Inhibition of ROS/ O2
- or NADPH oxidase activity is expressed as % 
of inhibition.  NADPH oxidase generation from rat aortic rings were expressed as 
average counts per mg of vessel dry weight (count/mg).   
 
2.6 Literature review of clinical adverse reactions and drug reactions of Danshen 
The following terms and their combinations were used to search major databases 
including PubMed, Proquest and CINHAL for the literature review: “clinical”, 
“adverse”, “reactions”, “events”, “drug”, “Danshen”, and “Salvia miltiorrhiza”
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Chapter Three 
 
 
Superoxide (O2-) scavenging activity of Danshen extracts and active 
compounds in cell free conditions 
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3.1 Background 
Previous studies have demonstrated the anti-oxidant activities of Danshen and its’ 
active compounds (Jiang, Lau et al. 2005; Shiao, Chiu et al. 2008).  Such activity may 
be linked to the capability of Danshen and Danshen compounds to scavenge ROS 
directly, or through actions on the endogenous enzymes which are responsible to 
produce ROS, including NADPH oxidase, XO, NOS and others previously mentioned 
(Munzel, Sinning et al. 2008).  There are still limited studies on direct effects of 
different Danshen extracts and purified compounds on ROS generation in the cell free 
system, and in particular the effects of Australian-grown Danshen has not been 
studied.  Therefore, the aim of research described in this chapter was to investigate 
firstly the effects of Australian grown Danshen extracts and related active compounds 
on ROS generation in a cell free system.  The system we used was xanthine-xanthine 
oxidase assay, a well characterised system for studying cell free O2
- scavenging 
(Wilhelm and Vilim, 1986), and used here for O2
- scavenging activity of aqueous and 
ethanol extracts of Danshen including TanIIA, SalB and DSS.  The mechanism of 
ROS (mainly O2
- and H2O2) generation from xanthine-xanthine oxidase assay is 
illustrated in the following scheme below (Doehner, Schoene et al. 2002). 
 
XO is able to transfer its substrates to the production of O2
- and H2O2.   
 
Hypoxanthine + H2O + O2 → Xanthine + 2H+ + 2 O2- 
Hypoxanthine + H2O + O2 → Xanthine + H2O2 
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3.2 Method 
ROS production from xanthine-xanthine oxidase was determined by Lucigenin assay 
(see Chapter 2, Section 2.3.2).   In brief, a solution of 5 µM lucigenin and XO 0.01 
U/ml was prepared.  Aliquots (180 µl) of the lucigenin/ XO solution were added to 
individual wells of a 96 well plate.  Treatments were applied in triplicates with either 
SOD 250 U/ml, Danshen test compounds or vehicle.  Wells containing 5 µM 
lucigenin only (200 µl) served as background.  HX at a final concentration of 100 µM 
was added to each well and the optiplate was read in the FLUOstar OPTIMA 
Microplate reader (Fig. 2.3) for 12 cycles at 5 seconds per well.   
 
3.3 Data Analysis and Statistics 
Results are expressed as mean ± standard error of mean (S.E.M).  Number of 
experiments is denoted by n.  Evaluation of statistical significance between 
inter-group differences was conducted using Student’s paired t-test.  Differences 
between groups were considered to be statistically significant with probability (P) 
values <0.05.  Inhibition of ROS generation is expressed as % inhibition.  Data is 
presented as percentage of inhibition, where the control is normalised to 100%.     
 
3.4 Results 
The ROS generation by XO/ HX was abolished by SOD (250 U/ml). 
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3.4.1 ROS scavenging activity of Danshen extracts 
The aqueous extract of Australian grown Danshen (0.01-0.5 mg/ml) significantly 
inhibited ROS generation in a concentration dependent manner (Fig. 3.1).  
Similarily, the ethanol extract of Australian grown Danshen (0.001-0.1 mg/ml) also 
demonstrated concentration-dependent inhibition of ROS generation, however it was 
significant only at higher concentrations (0.01 and 0.1 mg/ml), the ethanol extract 
showed a more potent inhibition than that of the aqueous extract.  In fact, at 0.1 
mg/ml the inhibition by the ethanol extract was similar to that of SOD (See Fig. 3.2) 
 
3.4.2 ROS scavenging activity of TanIIA, SalB and DSS 
At the concentrations tested, only 0.5 µM of TanIIA significantly inhibited ROS 
generation, while lower concentrations (1nM, 10nM, 0.1µM) did not show any 
significant effect on ROS generation. 
 
On the other hand, SalB significantly inhibited ROS generation at lower 
concentrations (10nM, 0.1 and 1 µM), and DSS only significantly inhibited ROS 
generation at concentrations above 1 µM (1, 10 and 50 µM).  Greater inhibition was 
demonstrated at higher concentrations of SalB and DSS, 1µM, and 10µM and 50µM, 
respectively.  (See Fig. 3.4 and Fig. 3.5).   
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Figure 3.1. Inhibitions by Danshen aqueous extract on ROS produced by xanthine 
oxidase/ hypoxanthine in a cell free system.   
 
O2
- generation in Krebs’ solution generated by xanthine oxidase (XO, 0.01 
U/ml)/hypoxanthine (Hx, 100µM) and detected via lucigenin (5 µM) in the presence 
of either Danshen aqueous extract [0.1mg/ml, 0.05mg/ml, 0.5mg/ml, 0.1mg/ml], 
superoxide dismutase (SOD) 250 U/ml, *p<0.05, ***p<0.001, Student’s paired t-test,  
n = 4.  The data is presented as percentage of inhibition, where the control is 
normalised to 100%.  Values are given as mean ± SEM. 
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Figure 3.2. Inhibitions by Danshen ethanol extract on ROS produced by xanthine 
oxidase/ hypoxanthine in a cell free system。  
 
O2
- generation in Krebs’ solution generated by xanthine oxidase (XO, 0.01 
U/ml)/hypoxanthine (Hx, 100µM) and detected via lucigenin (5 µM) in the presence 
of either Danshen ethanol extract [0.001mg/ml, 0.01mg/ml, 0.1mg/ml], superoxide 
dismutase (SOD) 250 U/ml, *p<0.05, ***p<0.001, Student’s paired t-test, n = 4.  The 
data is presented as percentage of inhibition, where the control is normalised to 100%.  
Values are given as mean ± SEM. 
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Figure 3.3. Inhibitions by Danshen compound tanshinone IIA on ROS produced by 
xanthine oxidase/ hypoxanthine in a cell free system.   
 
O2
- generation in Krebs’ solution generated by xanthine oxidase (XO, 0.01 
U/ml)/hypoxanthine (Hx, 100µM) and detected via lucigenin (5 µM) in the presence 
of either Danshen compound tanshinone IIA [1nM, 10nM, 0.1µM, 0.5µM], 
superoxide dismutase (SOD) 250 U/ml, *p<0.05, ***p<0.001, Student’s paired t-test, 
n = 4.  The data is presented as percentage of inhibition, where the control is 
normalised to 100%.  Values are given as mean ± SEM. 
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Figure 3.4. Inhibitions by Danshen compound salvianolic acid B on ROS produced 
by xanthine oxidase/ hypoxanthine in a cell free system.   
 
O2
- generation in Krebs’ solution generated by xanthine oxidase (XO, 0.01 
U/ml)/hypoxanthine (Hx, 100µM) and detected via lucigenin (5 µM) in the presence 
of either Danshen compound salvianolic acid B [1nM, 10nM, 0.1µM, 1µM, 10µM], 
superoxide dismutase (SOD) 250 U/ml, *p<0.05, ***p<0.001, Student’s paired t-test, 
n = 4.  The data is presented as percentage of inhibition, where the control is 
normalised to 100%.  Values are given as mean ± SEM. 
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Figure 3.5 Inhibitions by Danshen compound danshensu on ROS produced by 
xanthine oxidase/ hypoxanthine in a cell free system.   
 
O2
- generation in Krebs’ solution generated by xanthine oxidase (XO, 0.01 
U/ml)/hypoxanthine (Hx, 100µM) and detected via lucigenin (5 µM) in the presence 
of either Danshen compound danshensu [0.1µM, 1µM, 10µM, 50µM], superoxide 
dismutase (SOD) 250 U/ml, *p<0.05, ***p<0.001, Student’s paired t-test, n = 4.  The 
data is presented as percentage of inhibition, where the control is normalised to 100%.  
Values are given as mean ± SEM. 
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3.5 Discussion 
Danshen has been previously shown to have protective effects against oxidative stress 
(see Chapter 1), although the anti-oxidant effects of Australian grown Danshen have 
not been studied.  The findings of the present study showed that both aqueous and 
ethanol extracts of Australian grown Danshen significantly reduced ROS levels, 
indicating that Danshen may act as a ROS scavenger.  This action was similar to 
SOD. 
 
The ethanol extract of Australian grown Danshen showed more potent ROS 
scavenging activity than that of the aqueous extract as 0.01 mg/ml of the ethanol 
extract significantly reduced the ROS levels, while that of aqueous extract did not, and 
0.1 mg/ml of the ethanol extract produced more inhibition than that of aqueous extract.  
It is possible that the effects of these extracts are mediated by the active compounds in 
these extracts.  This is supported by the findings that both the lipophilic compound 
(TanIIA) and hydrophilic compounds (SalB and DSS) had significant O2
- scavenging 
activity.  In this regard, SalB exhibited slightly more potent scavenging activity than 
that of TanIIA, and both of these compounds were more effective than DSS.  Since 
the ethanol extract contains both hydrophilic and lipophilic active compounds, while 
the aquous extract does not contain TanIIA, the present findings indicate that ethanol 
extract of Australian grown Danshen may achieve a better anti-oxidant activity than 
the aqueous extract.  Interestingly, very low concentrations of TanIIA showed a 
tendency of slightly increased ROS levels (Fig. 3.3) this effect was not observed for 
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other Danshen compounds and Danshen extracts.  The reason for this is not clear, 
however it may be possible that TanIIA has two effects; at low concentrations it can 
facilitate the chemical process of ROS generation, while at higher concentrations acts 
as a O2
-  scavenger.  It is not clear if such effects of TanIIA can occur for endogenous 
generation at O2
- at physiological conditions. 
 
The present findings are in line with previous reports on the hydrophilic active 
compounds of Danshen, such as SalA, SalB and rosmarinic acid, which have been 
shown to inhibite the xanthine-xanthine oxidase mediated ROS production in cell free 
systems (Huang and Zhang 1992).  Of these, SalB inhibited ROS formation in a 
concentration dependent manner at 10-4 mol/L and 10-5 mol/L (Huang and Zhang 
1992).  Additionally, in a comparative study of SalB and Ginko biloba extract 
(EGb761) in aqueous solution, rat microsomes and the cellular system (Liu, Cheng et 
al. 2006), O2
- was generated using the xanthine/ xanthine oxidase system.  Both SalB 
and EGB761 were able to scavenge O2
-, however SalB was demonstrated to be more 
potent than that of EGb761 (Liu, Cheng et al. 2006).  The stronger action of SalB as 
O2
- scavenger indicates that it may be a preferential compound to other Danshen 
compounds in treating oxidative stress related diseases. 
 
In the present study, TanIIA was found less effective than SalB in scavenging ROS.  
Wu et al. (1993) previously demonstrated that STS, a salt form of TanIIA did not 
inhibit O2
- generation by XO (Wu, Zeng et al. 1993).  However, it did protect the 
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survival of human ventricular myocytes in vitro when cells were repeatedly exposed 
to XO-generated ROS (Wu, Zeng et al. 1993), indicating other actions may be 
involved. 
 
Compared to SalB and TanIIA, DSS showed weaker ROS scavenging activity, only 
effective at high concentrations (>1 µM).  A dose dependent inhibition by DSS was 
also observed in the present study with 50 µM produced >80% inhibition of ROS 
production.  This finding is consistent with previous studies (Zhou et al. 1996.; Zhao 
et al. 1996).  Zhou et al. (1996) previously studied the scavenging effects of Danshen 
on free radicals and its’ protection of myocardial mitochondria membranes from 
ischaemia-reperfusion injury and demonstrated that DSS was effective in scavenging 
ROS generated by the reaction of xanthine and XO by ESR technique (Zhao, Jiang et 
al. 1996) at 20 µM (scavenged approximately 57%  activity) and 200 µM (almost 
100% activity). 
 
3.6 Conclusion 
The findings described in this chapter demonstrate that both aqueous and ethanol 
extracts of Australian grown Danshen exhibit a direct ROS scavenging activity, 
similar to SOD, although the ethanol extract is more effective in this action.  The 
effect of these Danshen extracts may be mediated by the active compounds involved, 
including TanIIA, SalB and DSS.  It would be interesting to investigate further if 
such activity can be demonstrated in vascular tissue.  The ROS scavenging activities 
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of Danshen extracts and active compounds may be implicated in their actions in 
treating cardiovascular disease. 
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Chapter Four 
 
 
Effect of Danshen extracts and active compounds on NADPH oxidase 
derived superoxide (O2-) generation in isolated rat aorta. 
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4.1 Background 
NADPH oxidase constitutes as the primary source of O2
- in endothelial and vascular 
cells and whose primary function is ROS generation (Berry, Hamilton et al. 2000; 
Muzaffar, Jeremy et al. 2003; Touyz and Schiffrin 2004; Zalba, Beloqui et al. 2005; 
Dworakowski, Alom-Ruiz et al. 2008).  Previous studies have firmly established that 
NADPH oxidase mediated O2
- production plays an important role in endothelium and 
vascular smooth muscle dysfunction (See Chapter1). 
 
From findings described in Chapter 3, it is clear that the Australian-grown Danshen 
extracts and Danshen active compounds can directly scavenge ROS.  This may 
explain their anti-oxidant actions.  However, it is not clear if these extracts and 
compounds can effect the production of endogenous O2
- produced from NADPH 
oxidase in vascular tissue.  Therefore, the aim of the study described in this chapter 
was to investigate the effects of Australian-grown Danshen extracts and active 
compounds on NADPH oxidase deried O2
- generation in isolated rat aorta.   
 
4.2 Methods 
Vascular NADPH oxidase production was determined by lucigenin-enhanced 
chemiluminescence assay (See Chapter 2, Section 2.3.4).  In brief, following 
acclimatisation period, animals were deeply anaethetised with Ketamine (60mg/kg) 
and Xylaine (6mg/ kg)  by  intraperitoneal injection (D.O.P 2004).  The loss of foot 
pads and corneal reflexes was used to indicate deep anaesthesia (ANZCCART 2001) 
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prior to the exposure of the heart by surgical opening of the chest cavity.  The heart 
was then removed and cooled in ice-cold buffered Hepes-buffered Krebs solution.  
(See Chapter 2 for detail).   
 
4.2.1  Tissue preparation and NADPH oxidase assay 
See Chapter 2.  In brief, aortic sections (2-3mm in length) from each rat was collected 
and incubated in incubation solutions of 2 ml containing DETCA (3 mM) and 
NADPH (100µM) for 45 minutes, with one segment incubated without NADPH.  
During the incubation period, segments incubated with NADPH were treated with 
either NOX inhibitor DPI, concentrations of Danshen extract and compounds or no 
treatment as a control.  Following the incubation period, aortic rings were transferred 
into corresponding optiplate wells and the plate was read in the FLUOstar OPTIMA 
Microplate reader for 12 cycles at 5 seconds per well.  O2
- content within tissues was 
determined by subtracting the background (B) reading from the final reading (R) then 
dried aortic rings weighed (W) and O2
- content calculated via the following equation:  
 
Superoxide (O2
-) count (S) = R – B, superoxide content/mg = S/W.   
 
4.3 Data Analysis and Statistics 
Results are expressed as mean ± standard error of mean (S.E.M).  Number of 
experiments is denoted by n.  Evaluation of statistical significance between 
inter-group differences was conducted using Student’s paired t-test.  Differences 
  
 69
between groups were considered to be statistically significant with probability (P) 
values <0.05 were deemed significant.  Data is presented as percentage inhibition 
where the control is normalised to 100%.  Inhibition of NADPH oxidase activity is 
expressed as percentage inhibition of NADPH oxidase.  NADPH oxidase generation 
from rat aortic rings were expressed as average counts per mg of vessel dry weight 
(count/mg).  
 
4.4 Results  
In the presence of vehicles, the level of O2
- generation (or NADPH oxidase activity) 
was almost abolished by the NADPH oxidase inhibitor DPI (5µM) (See Fig. 4.1-4.5) 
 
4.4.1 Effects of Danshen extracts on NADPH oxidase derived O2
- generation 
In the concentration range tested, low concentration of aqueous (0.01 mg/ml, 0.5 
mg/ml and 0.1 mg/ml) and ethanol extracts (0.001 mg/ml, 0.01 mg/ml) of Australian 
grown Danshen did not significantly affect the NADPH oxidase activity.  At 
relatively high concentrations, 0.5 mg/ml for aqueous extract and 0.1 mg/ml for 
ethanol extract, these compounds significantly inhibited the NADPH oxidase derived 
O2
- generation.  The ethanol extract at 0.1 mg/ml produced a similar inhibition as 0.5 
mg/ml aqueous extract.  (See Fig. 4.1 and Fig. 4.2). 
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4.4.2 Effects of TanIIA, SalB and DSS on NADPH oxidase derived O2
- 
generation.  
NADPH oxidase derived O2
- generation was not significantly affected by low 
concentrations of SalB (1 nM – 0.1 µM) and DSS (0.1 µM).  However, it was 
significantly affected by higher concentrations of SalB (1 and 10 µM) and DSS (1-50 
µM) (See Fig. 4.3-4.5).  Concentrations tested using TanIIA did not show any 
significant inhibition on NADPH oxidase derived O2
- (See Fig. 4.3). 
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Figure 4.1. Effect of Danshen aqueous extract on NADPH (100 µM) stimulated 
O2
- generation in aortic tissue from male Sprague-Dawley rats by lucigenin assay. 
 
Superoxide (O2
-) generation in aortic rings from male Sprague-Dawley rats via 
NADPH (100 µM) stimulation detected via lucigenin (5 µM) in the presence of 
Danshen aqueous extract [0.01mg/ml, 0.05mg/ml, 0.5mg/ml, 0.1mg/ml], control or 
the NOX inhibitor DPI 5 µM, *p<0.05,  ***p<0.001, Student’s paired t-test, n = 4.  
The data is presented as percentage of inhibition where the control is normalized to 
100%.  Values are given as mean ± SEM.  
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Figure 4.2.  Effect of Danshen ethanol extract on NADPH (100 µM) stimulated 
O2
- generation in aortic tissue from male Sprague-Dawley rats by lucigenin assay. 
 
Superoxide (O2
-) generation in aortic rings from male Sprague-Dawley rats via 
NADPH (100 µM) stimulation detected via lucigenin (5 µM) in the presence of 
Danshen ethanol extract [0.001mg/ml, 0.01mg/ml, 0.1mg/ml], control or the NOX 
inhibitor DPI 5 µM, *p<0.05, ***p<0.001, Student’s paired t-test, n= 4-7.  The data is 
presented as percentage of inhibition where the control is normalized to 100%.  
Values are given as mean ± SEM.  
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Figure 4.3. Effect of Danshen compound tanshinone IIA on NADPH (100 µM) 
stimulated O2
- generation in aortic tissue from male Sprague-Dawley rats by lucigenin 
assay. 
 
Superoxide (O2
-) generation in aortic rings from male Sprague-Dawley rats via 
NADPH (100 µM) stimulation detected via lucigenin (5 µM) in the presence of 
Danshen compound tanshinone IIA [1nM, 10nM, 0.1µM, 0.5µM], control or the NOX 
inhibitor DPI 5 µM, *p<0.05,  ***p<0.001, Student’s paired t-test, n = 4.  The data is 
presented as percentage of inhibition where the control is normalized to 100%.  
Values are given as mean ± SEM.  
 
 
 
 
 
 
  
 74
 
 
 
Figure 4.4. Effect of Danshen compound salvianolic acid B on NADPH (100 µM) 
stimulated O2
- generation in aortic tissue from male Sprague-rats by lucigenin assay. 
 
Superoxide (O2
-) generation in aortic rings from male Sprague-Dawley rats via 
NADPH (100 µM) stimulation detected via lucigenin (5 µM) in the presence of 
Danshen compound salvianolic acid B [1nM, 10nM, 0.1µM, 1µM, 10µM], control or 
the NOX inhibitor DPI 5 µM, *p<0.05, ***p<0.001, Student’s paired t-test, n =  5-6.  
The data is presented as percentage of inhibition where the control is normalized to 
100%.  Values are given as mean ± SEM.  
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Figure 4.5. Effect of Danshen compound danshensu on NADPH (100 µM) stimulated 
O2
- generation in aortic tissue from male Sprague-Dawley rats by lucigenin assay. 
 
Superoxide (O2
-) generation in aortic rings from male Sprague-Dawley rats via 
NADPH (100 µM) stimulation detected via lucigenin (5 µM) in the presence of 
Danshen compound danshensu [0.1µM, 1µM, 10µM, 50µM], control or the NOX 
inhibitor DPI 5 µM, *p<0.05, ***p<0.001, Student’s paired t-test, n = 3-5.  The data 
is presented as percentage of inhibition where the control is normalized to 100%.  
Values are given as mean ± SEM.  
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4.5 Discussion 
Findings as described in Chapter 3 showed Australian grown Danshen may act as a 
direct ROS scavenger.  However, it is not clear if Danshen and its’ active compounds 
can effectively inhibit endogenous NADPH oxidase derived O2
- productions in 
vascular tissue.  By using isolated rat aortic tissues incubated in physiological 
solutions, the effects of Danshen extracts and active compounds were investigated in 
the present study. The findings that both Danshen aqueous and ethanol extracts 
inhibited NADPH oxidase derived O2
- generation at relatively high concentrations in 
isolated rat aorta, indicated that it may act as a weaker NADPH oxidase scavenger in 
active compounds of Danshen.  DPI, an inhibitor of NADPH oxidase, also 
significantly inhibited NADPH oxidase generation.  The findings of DPI supports the 
previous suggestion that NADPH oxidase is a major source of O2
- in the vascular 
tissue (Touyz and Schiffrin, 2004). 
 
The aqueous Danshen extract appears slightly less effective than that of ethanol 
extract, which is consistent with results in Chapter 3 (See Fig. 3.1 & Fig. 3.2).   It is 
possible that the hydrophilic active compounds may contribute more to the inhibition 
by Danshen on NADPH oxidase induced O2
- production as both SalB and DSS 
inhibited NADPH oxidase activity while TanIIA did not, although caution should be 
taken as higher concentrations of TanIIA was not tested in the present study.  Further 
research is necessary to establish the difference in potency of these active compounds. 
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The inhibition of NADPH oxidase derived O2
- production by Danshen extracts and 
active compounds was not as obvious in ex vivo conditions compared to cell free 
system.  For example, Danshen aqueous extract significantly inhibited ROS 
production at concentrations of 0.05 mg/ml and 0.1 mg/ml in cell free conditions while 
it only inhibited NADPH oxidase derived O2
- production at 0.5 mg/ml in the rat aorta.  
Similar pattern of actions was also observed for  Danshen ethanol extract and SalB.  
Interestingly, TanIIA at 0.5µM exhibited significant inhibition in cell free conditions 
but it had no significant effect in ex vivo conditions.  This suggests that Danshen 
extracts and compounds are less active towards NADPH oxidase derived O2
- 
generation, or other factors may affect their activities such as access factors or rate of 
reaction.  However, DSS did exhibit similar inhibitory effects in both cell free and ex 
vivo conditions.  It may be compound dependent.  Further studies are necessary to 
elucidate the mechanisms involved.   
 
The present findings are consistent with previous reports by Zhang and Wang (2006), 
showing that SalB had inhibitory effects against NADPH oxidase derived ROS 
(Zhang and Wang 2006).  They demonstrated that SalB inhibited TNF-α-induced 
matrix metalloproteinase-2 (MMP-2) up-regulation in human aortic smooth muscle 
cells (HASMC) via suppression of NADPH oxidase derived ROS.   
 
SalB has previously been demonstrated to significantly inhibit ROS at 20µg/mL in rat 
smooth muscle cells (Hung, Wang et al. 2006), although its’ actions on NADPH 
  
 78
oxidase was not investigated.  Zhang and Wang (2006) demonstrated that SalB to 
inhibited TNFα-induced NADPH oxidase activity in HASMC, however SalB alone 
did not affect NADPH oxidase activity (Zhang and Wang 2006).  In addition, a 
further study by Yin et al (2008), demonstrated inhibition of NADPH oxidase by a 
standard fraction (SF) of the root of Salvia miltiorrhiza in RAW 264.7 cells (Yin, Kim 
et al. 2008).  They reported that Sm-SF reduced the production of LPS or 
ethanol–induced ROS production significantly at the highest concentration tested 
(50µg/mL), however no significant inhibition was observed for Sm-SF at 
concentrations of 1µg/mL, 5µg/mL and 10µg/mL.  Such inhibitory activity of 
Danshen extracts was not observed in the present study.  It is not clear if an access 
factor ie) penetration of the vascular tissue would be more difficult than in cultured 
cells and that this may contribute to this difference observed.  In addition, ROS is 
understood to be highly localised and such that, the assay of a segment of tissue might 
not reflect a subcellular increase (Didalov, Griendling et al. 2007).  The concentration 
of ROS at the site of production could be extremely high, and this may not be reflected 
by measurements obtained in intact tissue.  To date, there are no similar reports in the 
literature on the effect of Danshen extracts or compounds on NADPH oxidase in rat 
aorta or other vessel tissues to evaluate our study.  Furthermore, it is understood that 
it is very unlikely that any probe will react with all of the ROS produced, thus the 
assay cannot be viewed as completely quantitative   (Didalov, Griendling et al. 
2007).  These factors may account for the variable results obtained.  Finally, to our 
knowledge, this is the first ex vivo study to investigate inhibition of NADPH oxidase 
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derived O2
- production by Australian grown Danshen aqueous and ethanol extracts.  
It is yet to be established if such actions of these Danshen extracts can be observed in 
vivo, and more importantly, if combination of various compounds or extracts may 
produce a better therapeutic action.  The later is important in clinical practice since 
the traditional way of using Danshen is via complex herbal formulations. 
 
4.6 Conclusion 
NADPH oxidase is understood to be a major source of O2
- in vascular tissues, thus 
playing a key role in cardiovascular disease.  This study has provided evidence that 
Australian-grown Danshen extracts and active compounds of Danshen have 
inhibitory actions on NADPH oxidase derived O2
- production in rat aorta.  These 
findings highlight the potential use of Danshen as a therapeutic agent in various 
diseases where O2
- generation from over-expression and activity from NADPH 
oxidase is prominent. 
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Chapter 5 
 
 
Clinical adverse reactions and drug interactions of Danshen 
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5.1  Adverse drug reactions (ADR) and CHM 
ADR are defined as ` an appreciably harmful or unpleasant reaction, resulting from an 
intervention related to the use of a medicinal product, which predicts hazard from 
future administration and warrants prevention or specific treatment, or alteration of 
the dosage regimen, or withdrawal of the product (Edwards and Aronson 2000)’.  
According to the WHO, reactions are to be reported by use of WHO’s Adverse 
Reaction Terminology under six classifications: dose-related, non-dose-related, 
dose-related and time-related, time-related, withdrawal, and failure of therapy 
(Edwards and Aronson 2000). 
 
5.1.1 Reporting adverse drug reactions for CHM 
Bensoussan and Myers (1996) acknowledge it is impossible to estimate the rate of 
adverse events for CHM since the total exposure to a particular medicinal substance is 
unknown (Bensoussan and Myers 1996).  A study conducted by Xue et al. (2007) 
indicated that less than half of all CAM users from a study on CAM use in Australia 
informed their medical practitioners about their use of CAM (Xue, Zhang et al. 2007). 
 
5.1.2 Clinical significance of adverse drug reactions and CHM 
The most common adverse events reported for CHM noted by Bensoussan and Myers 
(1996) were severe gastrointestinal symptoms, fainting and dizziness and significant 
skin reactions and serious adverse events reported included central nervous system 
effects, hepatotoxicity, renal toxicity and death.   
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As CAM use in Australia, and in particular herbal medicines usage, including CHM 
continues to increase, clinical significance of ADR’s is paramount toward ensuring 
patient safety.  
 
The aim of this chapter is to review clinical adverse reactions and drug reactions of 
Danshen.  
 
5.2 Methodology for review of clinical adverse reactions and drug reactions of 
Danshen 
For the following literature review, “clinical”, “adverse”, “reactions”, “events”, 
“drug”, “Danshen” and “Salvia miltiorrhiza” and their combinations were used to 
search the major databases including PubMed, Proquest and CINHAL.    
 
5.3 Clinical adverse reactions of Danshen 
Few studies designed to specifically determine the clinical adverse reactions of 
Danshen have been performed.  Bo et al. (2008) conducted a Cochrane review on 
Danshen agents for Acute Ischaemic Stroke (Bo Wu 2008).  The Cochrane review 
analysed systematically all the randomised or quasi-randomised controlled trials 
comparing Danshen agents with no Danshen agents in patients with Acute Ischaemic 
Stroke.  However, the review was unable to conclude the efficacy or adverse events 
associated with Danshen agents (Bo Wu 2008).  Due to the limited number of trials 
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identified, limited duration of treatment and inadequate recording and reporting of 
adverse events, such conclusions could not be drawn.  The review suggested high 
quality, large scale trials are required to confirm the efficacy, and in turn, adverse 
events of Danshen agents.  The review involved six trials involving 494 patients, 
however only 2 trials reported on adverse events (Bo Wu 2008).  Studies included in 
the review, Min (2003) and Zhang (2002) reported drowsiness had occurred in 31 
patients in the first week, and disappeared in the second week after administration of 
Danshen (Zhang, Zhang et al. 2002; Min, Yuan et al. 2004).  Nine participants 
presented with thrombocytopenia in the second week and three patients experienced 
dizziness.  These conditions were reported to have improved after ceasing of 
Danshen.  It was further reported that there was no difference between the treatment 
group and the control group for adverse events.  However, the review by Bo et al. 
(2008) suggested that the methodological quality of all included studies were poor and 
reliable conclusions could not be drawn from the presenting data.  The study did 
suggest that Danshen agents appeared to have few adverse effects (Bo Wu 2008). 
 
The occurrence of adverse events from taking Danshen during trials of healthy and 
non-healthy subjects in various disease states have been reported.  (See Table 5.1.) 
 
5.4 Clinical adverse events of Danshen formulations 
The commonly used preparation of capsulated DDP (See Section 1.1.4.2 and Fig. 1.4) 
containing Danshen, San Qi (Panax notoginseng) and Bing Pian (Cinnamomum 
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camphora （ ）) have been well studied.  Yafeng et al. 2011 performed a 
meta-analysis of randomised controlled trials comparing DDP with isosorbide 
dinitrate (ID) in treatment of stable angina (Yafeng, Yanli et al. 2011).  The study 
included fifteen randomised controlled trials including 1536 patients that included 847 
patients receiving DDP therapy and 689 receiving ID therapy.  The study suggested 
that DDP is an effective treatment option to treat stable angina and noted some adverse 
events.  Some of the studies showed there were mild gastrointestinal reactions during 
administration of DDP.  Patients were willing to continue the DDP treatment after 
taking other gastrointestinal drugs.  Furthermore, taking the pill in conjunction with 
food limited the effect of gastrointestinal effects.  It was identified from the study that 
the current data from the randomised controlled trials did not incorporate a full 
analysis of drug safety and that more trials regarding side effects of DDP are required 
to evaluate the safety (Yafeng, Yanli et al. 2011).  The USA FDA has at present 
approved the safety and effectiveness of DDP with Phase II clinical trial completed in 
July 2010 (Yafeng, Yanli et al. 2011) and Phase III trials under completion. 
 
A double-blind, placebo-controlled randomised single centre study clinical trial 
evaluating the effects of a variation of the Fu Fang Danshen extract capsule in patients 
with uncontrolled blood pressure was performed (Yang, Wei et al. 2011).  A 500mg 
capsule contained 225mg purified Danshen extract, mixed with 20mg Rhodiola rosea 
extract (Hong Jing Tian), 100mg Chysanthemum extract (Ju Hua), and 100mg 
Puerana extract.  The study involved fifty patients with uncontrolled mild to 
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moderate hypertension under previous conventional anti-hypertensive treatment, 
randomised to receive Fu Fang Danshen capsule twice daily, or a placebo.  The 
results suggested Fu Fang Danshen extract reduced systolic blood pressure and pulse 
rate and was well tolerated in patients with hypertension (Yang, Wei et al. 2011).  
Few adverse events were reported (See Table 5.1) with no adverse events statistically 
significant between the study and control group.  Anti-hypertensive drugs and any 
other drugs that might have affected blood pressure were prohibited during the trial 
period. 
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Table 5.1  Adverse events during Danshen Trials (Healthy & Non-Healthy Subjects) 
Danshen 
preparation 
Disease Main Effect Reference 
Yun Zhi and Danshen 
capsules (Oral 
administration) 
 
 
Danshen Dripping 
Pill (Oral 
administration) 
 
Danshen extract (Oral 
Healthy Subjects 
 
 
 
 
Heart Disease 
 
 
 
Angina Pectoris 
18/100 subjects left study prior to its 
duration with reports of unpleasant 
stomach feelings in some participants  
 
 
3/100 participants reported thirst post 
administration of 10 pills sublingually 3 
times per day 
 
2/160 participants reported mild 
(Wong, Tse et al. 2004) 
 
 
 
 
(Zhou and Xiong 2003) 
 
 
 
(Xu 2000) 
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administration) 
 
Fufeng Danshen 
Dripping Pill (Oral 
administration) 
 
Fufeng Danshen 
Dripping Pill (Oral 
administration) 
 
Fufeng Danshen 
Tablet (Oral 
administration) 
 
 
Coronary Heart Disease & Angina 
Pectoris 
 
 
Angina Pectoris 
 
 
 
Coronary Heart Disease & Angina 
Pectoris 
 
gastrointestinal reaction 
 
3/142 participants reported mild 
gastrointestinal reaction 
 
 
2/56 participants reported headache 
 
 
 
2/34 participants reported upper 
abdominal discomfort, 3/34 participants 
reported bad appetite 
 
 
(Sun, Dai et al. 2000) 
 
 
 
(Wang and Wang 2004) 
 
 
 
(Jia and Du 2000) 
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Fufeng Danshen 
Dripping Pill (Oral 
administration) 
 
 
 
 
 
Danshen and Ge Gen 
(Oral administration) 
 
 
 
Uncontrolled hypertension 
 
 
 
 
 
 
 
Coronary Heart Disease 
 
 
 
 
13/25 participants reported adverse 
events; 1/25 elevation of glucose; 2/25 
diarrhoea; 1/25 dry cough; 1/25 
gastrointestinal upset; 1/25 dyspnoea; 1/25 
dysuria; 2/25 fatigue; 2/25 common cold; 
1/25 photosensitive dermatitis; 1/25 
alopecia 
 
6/100 placebo and 2/100 subjects 
experienced chest pain, left heart failure, 
sciatica and gastrointestinal bleeding (no 
specific findings detailed as to placebo and 
treatment group  
(Yang, Wei et al. 2011) 
 
 
 
 
 
 
 
(Tam, Chook et al. 2009) 
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Danshen (intravenous 
administration)  
 
Yun Zhi & Danshen 
capsules (Oral 
administration) 
Ischaemia and necrosis of skin flaps 
post mastectomy for Breast Cancer 
 
Breast Cancer 
1/30 participants reported dry mouth, 2/30  
participants experienced rubeosis 
 
Sore throat (13.4%), dry mouth (9.8%) 
 
(Chen, Lv et al. 2010) 
 
 
(Wong, Tse et al. 2004) 
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5.5 Herb-drug interactions of Danshen 
There has been an increasing popularity of herbal medicine usage, hence the potential 
for interaction between herbal products and pharmaceuticals products is of concern 
(Kennedy and Seely 2010).   
 
The underlying mechanisms for most reported herb-drug interactions are not fully 
understood, however pharmacokinetic and/ or pharmacodynamic mechanisms are 
implicated in many of these interactions (Gurley 2012; He, Sneed et al. 2012).   
Additionally, Gurley et al. (2012) and He et al. (2012) suggest enzyme induction and/ 
or inhibition may play an important role in the occurrence of some herb-drug 
interactions. 
 
5.5.1 Adverse Danshen and drug interactions of cardiovascular pharmacology 
case reports 
 
A review of herb-drug interactions between herbal medicine and conventional 
cardiovascular pharmacotherapy was conducted from 1966 to 2003 (Izzo, Di Carlo et 
al. 2005).  Forty-three case reports and eight clinical trials were identified from the 
review with warfarin being the most common cardiovascular drug involved.  
Warfarin was found to interact with Danshen and other herbs and plant derivatives 
including boldo, curbicin, fenugreek, garlic, devil’s claw, dang gui, ginko, papaya, 
lyceum, mango, ginseng, green tea, soy and St. John’s wort.  Other cardiovascular 
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drugs, including digoxin, aspirin, simvastatin, lovastatin, diuretic thiazide also had 
herb-drug interactions that potentiated the clinical therapeutic effect (Izzo, Di Carlo et 
al. 2005).  
 
5.6 Interactions between Danshen and conventional drugs  
Danshen has been shown from in vitro and in vivo studies to interact with various 
pharmaceutics in both animal and humans.   
 
Table 5.2 shows Danshen and drug reactions in vitro and Table 5.3 shows Danshen 
and drug reactions in vivo animal studies. 
 
Table 5.4 shows adverse Danshen and drug interactions of cardiovascular 
pharmacology in human case reports. 
 
5.6.1 Danshen and warfarin interactions 
Warfarin is an anti-coagulant drug prescribed for its’ anti-clotting agents to prevent 
heart attacks, stroke and blood clots. Danshen is understood to be involved in drug 
interactions in treatment of cardiovascular disease however studies currently present 
as inconsistent and varied.   
 
A Medline search performed from January 1996 to October 2000 with single-dose and 
steady-state warfarin studies in rats indicated that Danshen increased the absorption 
  
 92
rate constants, AUC’s, maximum concentration and elimination half-lives but 
decreased clearances and apparent volume of distribution of warfarin and hence, the 
anti-coagulation response to warfarin was exaggerated (Chan 2001).  The study 
concluded that due to both pharmacokinetic and pharmacodynamic interactions, 
Danshen should be avoided with patients taking warfarin (Chan 2001).  Studies 
indicate Danshen to have adverse effect when taken in conjunction with 
cardiovascular pharmacotherapies (Chan 2001) due to increased platelet aggregation, 
interference with the extrinsic blood coagulation, anti-thrombotic III activity-like 
activity and promotion of fibrinolytic activity, and seen to result in over coagulation 
and decreased clearance and volume of distribution of warfarin (Chan 2001).   
 
However, recent studies of DDP suggest the concomitant application of DDP and 
warfarin in rats does not give rise to significant effects on the pharmacodynamics of 
warfarin and little effect on its pharmacokinetics (Chu, Zhang et al. 2011).   
 
5.6.1.2  Danshen and warfarin interactions in animal studies 
Table 5.2 shows Danshen and drug reactions of drugs including warfarin, in-vitro.  
Table 5.3 shows Danshen and drug reactions including warfarin in animals, in-vivo.  
Absorption and clearance rates were shown to be affected.   
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5.6.1.3  Danshen and warfarin interactions in human studies 
Human case reports presented in Table 5.4 suggest adverse reaction with the patient 
taking Danshen and warfarin (Tam, Chan et al. 1995; Yu, Chan et al. 1997; Izzat, Yim 
et al. 1998). Significant ADR’s noted was over-coagulation and bleeding 
complications. 
 
5.7       Herb-drug interactions and the human cytochrome p450 
A key mechanism of herb-drug interactions are related to the inhibition of the enzyme 
CYP.  The common drugs that interact with herbal medicines include warfarin, 
midazolam, digoxin, amitriptyline, indinavir, cyclosporine, tacrolimus and irinotecan 
(He, Sneed et al. 2012).  It is understood that herbal medicines may interact with 
drugs at the intestines, liver, kidneys, and targets of action (He, Sneed et al. 2012). 
 
The study of herb-drug interactions has been identified via the impact of herbal 
products on CYP450 family of enzymes.  More than 30 human CYP isozymes have 
been identified and greater then 90% of the oxidative breakdown of human drugs can 
，be attributed to six main enzymes  CYP1A2, CYP2C9, CYP2C19, CYP2D6, 
CYP2E1, CYP3A4. 
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5.7.1 Danshen interactions with cytochrome p450 (in-vitro) 
Danshen preparation and compounds have been identified to interact with cytochrome 
p450 enzymes that have resulted in inhibition of CYP isozymes, suggesting Danshen 
may have herb-drug interactions.  See Table 5.5. 
 
However, recent studies have shown that Danshen had no substantial effect on the 
pharmacokinetics of docetaxel, an anti-neoplastic drug, and clopidogrel, an 
antiplatelet agent, when orally administered in rats (Lee, Shin et al. 2011).  The study 
suggested the negligible safety concern of Danshen in CYP3A-mediated interaction 
in-vivo (Lee, Shin et al. 2011).  
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Table 5.2 Danshen & drug reactions (in vitro) 
Danshen preparation Drug Interaction Reference 
Danshen extract 
 
 
Danshen preparation in ethyl 
acetate 
 
Danshen extract 
Warfarin 
 
 
Salicylate 
 
 
Tolbutamide 
Increased bioavailability of 
warfarin and affects elimination 
 
Increased free salicylate 
concentration 
 
Decreased tolbutamide formation 
(Lo, Chan et al. 1992) 
 
 
(Gupta, Jalali et al. 2002) 
 
 
(Wang, Lee et al. 2010) 
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Table 5.3 Danshen & drug reactions (in vivo) 
Danshen preparation  Drug Subject Interaction Reference 
Danshen extract 
 
 
 
Danshen aqueous extract 
 
 
 
 
 
 
Danshen extract 
 
R- & S- 
Warfarin 
sterioisomers 
 
Warfarin 
 
 
 
 
 
 
Docetaxel 
Clopidogrel 
SD rats 
 
 
 
SD rats 
 
 
 
 
 
 
SD rats 
 
Increase absorption and decrease clearance 
 
 
 
No effect on warfarin hydroxylation, acute and 3-day 
danshen treatment significantly reduced Cmax & 
Tmax of warfarin, formation of 
4’-&7-hydroxywarfarin was significantly reduced 
after 3 day danshen treatment, steady-state plasma 
warfarin concentration increased 
 
No effect of plasma concentrations and 
pharmacokinetic parameters 
(Chan, Lo et al. 1995) 
 
 
 
(Wu and Yeung 2010) 
 
 
 
 
 
 
(Gupta, Jalali et al. 2002; 
Lee, Shin et al. 2011) 
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Danshen extract 
 
 
 
Danshen extract 
 
Danshen extract 
Midazolam 
 
 
 
Tolbutamide 
 
Diazepam 
SD rats 
 
 
 
Winstar rats 
 
SD rats 
Decreased midazolam clearance, increased 
midazolam AUC and half-life, prolonged hypnotic 
effect 
 
Reduced tolbutamide formation 
 
Decrease of maximum concentration & area under 
plasma concentration time, total body clearance 
increase 
(Wang, Lee et al. 2010) 
 
 
 
(Wang, Lee et al. 2010) 
 
(Jinping, Peiling et al. 
2003) 
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Table 5.4 Adverse Danshen & drug interactions of cardiovascular pharmacology case reports 
Danshen preparation/ 
drug 
Main ADR Reference 
Danshen & warfarin 
 
 
Danshen & warfarin 
 
 
Danshen, Chinese 
medicated oil `Kwan 
Loong (15% methyl 
salicylate) & warfarin 
Over-coagulation 
Bleeding complications 
 
Melena, increased INR (Danshen effect), platelet dysfunction (salicylate 
effect) 
 
Increased INR, pleural and pericardial fluid collections 
(Yu, Chan et al. 1997) 
 
 
(Tam, Chan et al. 1995) 
 
 
(Izzat, Yim et al. 1998) 
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Table 5.5 Danshen interactions with human cytochrome p450 (in vitro) 
Danshen 
preparation/ 
compounds 
Tissue/ Cells/ 
Subjects 
CYP Form  Effect Reference 
 
 
Danshensu 
Protocatechuic 
aldehyde 
Tanshinone I 
 
Tanshinone IIA 
 
Cryptotanshinone 
 
Danshen ethanol 
extract 
 
 
Danshen aqueous 
extract 
 
 
Danshen ethyl 
acetate 
 
Danshen aqueous 
extract 
 
 
Danshen extract 
Human Liver 
Microsomes 
 
 
 
 
 
 
 
Human and rat liver 
microsomes 
 
 
Rat 
 
 
 
Mice 
 
 
Mice 
 
 
 
Rat 
CYP2C9 
CYP3A4 
 
CYP1A2 
CYP2D6 
CYP1A2 
CYP2C9 
CYP2D6 
 
CYP1A2 
CYP3A 
 
 
CYP1A 
CYP2C 
CYP3A 
 
CYP1A 
CYP3A 
CYP2C 
CYP1A 
CYP3A 
CYP2C  
 
CYP2C11 
Inhibit 
Inhibit 
 
Inhibit 
Inhibit 
Inhibit 
Inhibit 
Inhibit 
 
Inhibit 
Inhibit 
 
 
No effect 
No effect 
No effect 
 
Increase 
Increase 
No effect 
No effect 
No effect 
 
 
No effect 
(Qiu, Zhang et al. 2008) 
 
 
 
 
 
 
 
 
(Wang and Yeung 2011) 
 
 
 
(Kuo, Lin et al. 2006) 
 
 
 
(Jinping, Peiling et al. 2003) 
 
 
 
 
 
 
(Wang, Lee et al. 2010) 
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5.7.2 Clinical trials 
In vitro findings have shown human CYP1A2 is inhibited by Danshen compounds (DSS, 
pprotocatechuic aldehyde, TanI, TanIIA) and Danshen ethanol extract (Qiu, Wang et al. 
2008) (See Table 5.5).  The drug theophylline, used largely for treatment of respiratory 
diseases, including asthma and chronic obstructive airways disease, is largely metabolised 
by CYP1A2.  However, a clinical trial of 12 healthy subjects suggested that Danshen did 
not influence the metabolism of theophylline in healthy subjects.  No changes in 
pharmacokinetic parameters were shown (Qiu, Wang et al. 2008).  
 
5.8 Conclusion 
Clinical adverse reactions and drug interactions of Danshen are an important consideration 
in the future usage of CHM to ensure patient safety and efficacy.   Clinically, Danshen 
has been reported to cause few adverse events.  Danshen has been shown to affect the 
pharmacokinetic and pharmacodynamics of pharmaceuticals via drug metabolising 
enzymes and transporters, however more research is required to establish what effect 
Danshen may have on these enzyme systems, dose relationships and the clinical 
significance of such effects. 
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Chapter 6 
 
 
 General discussion and Conclusion  
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6.1 Main findings 
Extensive literature review, as described in Chapter 1, revealed important information on 
oxidant stress and vascular disease.  It also detailed the source, chemistry, pharmacology 
and clinical applications of Danshen and its’ active compounds. 
 
The results of the experiments as described in Chapter 3 and 4 have demonstrated that  
Danshen has an anti-oxidant effect in vitro. Danshen extracts and active compounds of  
Danshen (SalB, DSS and TanIIA) significantly inhibited ROS formation in the cell free 
system, which may be due to its’ direct ROS scavenging activity.  The anti-oxidant 
activity of Danshen is further confirmed in vascular tissue (rat aorta) with the findings that 
NADPH oxidase derived O2
- was inhibited by Danshen extracts and active compounds. 
 
Despite the difference observed in the potency and actions of different Danshen extracts 
and active compounds (as described in previous Chapter 3 and 4), the findings of this study 
provided the first in vitro evidence on the effects of Australian grown Danshen on ROS 
scavenging activity and NADPH oxidase derived O2
-, indicating the potential of using 
Australian grown Danshen for anti-oxidant applications, including treatment of NADPH 
oxidase related vascular disease. 
 
On the other hand, the literature review from clinical trials and experimental studies 
(Chapter 5) demonstrated Danshen to be generally well tolerated and safe in clinical use.  
The use of Danshen in clinical use was shown to have few adverse reactions.  However, 
certain caution should also be taken, including potential herb-drug interactions (Gurley 
  
 103 
2012; He, Sneed et al. 2012).  Danshen preparation and compounds have been shown to 
interact with certain drugs and also to interact with cytochrome p450 enzymes.  In 
addition, most previous clinical studies have been low quality, thus further high quality 
trails are necessary in order to establish the efficacy and safety of Danshen for treating 
cardiovascular disease states. 
 
6.2 Limitations of the study 
The present study has certain limitations. 
 
Firstly, due to the time limit, only a small number of individual Danshen compounds were 
tested.  The actions of other compounds and combination of various components were not 
studied.  In addition, the observations obtained are limited to the concentrations of the 
Danshen extracts or compounds tested.  Higher concentrations of these extracts or 
compounds of Danshen may have additional effects, although the effects at very high 
concentrations may not be clinically relevant as it is unlikely to achieve such high 
concentrations in vivo. 
 
Secondly, the limitation of ROS detection methods used may affect the findings.  Other 
measures such as expression of NADPH oxidase enzymes, or studying functional 
responses to endothelium-dependent relaxations may help to understand the further 
mechanisms of actions of Danshen. 
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Thirdly, findings from in vitro experiments do not necessarily correlate to in vivo results as 
other factors such as complex interactions between different regulatory systems in vivo 
conditions and drug metabolism processes may modify the actions of these compounds in 
vivo.  Thus, further research is necessary to establish the relevant actions of these Danshen 
extracts and compounds in vivo. 
 
6.3 Future Direction 
The findings from the present work lay a foundation for possible further works.  These 
include: 
1)  Detailed analysis of actions of Danshen extracts and active compounds on   
NADPH oxidase pathways, including expression of NOX genes and proteins 
2)  Detailed analysis of actions of other individual Danshen compounds and their 
combinations on ROS scavenging activity and inhibition of NADPH oxidase 
derived O2
- 
3) Effects of Danshen extracts and compounds on endothelium functions in vitro 
and in vivo 
4) Concentrations of Danshen active compounds in vivo and their relationship with 
in vitro pharmacological actions 
5) Comparison of actions of different sources of Danshen 
6) Clinical trials of potential herb-drug interactions 
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6.4 Conclusion 
Australian grown Danshen extracts and related bioactive compounds have been 
demonstrated to be effective in scavenging ROS generation in a cell free system and in 
NADPH oxidase derived O2
- in vascular tissue.  Overall, Danshen extracts and their active 
compounds (TanIIA, SalB and DSS) exhibited a stronger activity in the cell free system 
than in the aortic vascular tissue.  Such actions of Danshen may contribute to 
understanding its’ pharmacological actions that has been well documented.  However, 
certain adverse reactions and potential herb-drug interactions have been reported with 
Danshen, which may have clinical implications.
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